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INTRODUCTION 
 
Lung cancer epidemiology 
 
Lung cancer is the leading cause of death due to cancer worldwide: in 2005 World Health 
Organization (WHO) estimated 1.5 million new lung cancer cases (1.1 million among men and 440,000 
among women) (about 12% of total cancer diagnoses) and about 975,000 men and 376,000 women 
projected to die from it worldwide (1). 
 Also in European Country lung cancer is the most common cause of cancer death with 
334,800 (19.7% of the total), but not the most frequently cancer diagnosed, following breast and 
colorectal cancer, with 386,300 new cases (12.1% of the total) in the 2006 (2). Specifically, in Italy 
lung cancer is the first cause of death among men and the second among women accounting for 25,639 
and 6,495 deaths respectively in 2002, with a corresponding mean incidence of 111.5 and 27.9 new 
cases per 100,000 every year (3). 
Cigarette smoking is the most important risk factor, accounting for about 80% of lung cancer 
cases in men and 50% in women worldwide (4).  
 
Occupational risk factors 
 
Among the other environmental risk factors for lung cancer, occupation is the most relevant: 
since 1972 the International Agency for Research on Cancer (IARC) Monograph Program published 
almost 100 volumes, reporting evaluations of about 1,000 substances, complex mixtures, and industrial 
processes (5). In a recent review of these occupational carcinogens, 18 occupations/industries and 
substances that possibly, probably or definitely (IARC groups 2B, 2A, and 1, respectively), entail an 
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excess risk, with strong evidence for lung cancer, were listed: aluminium production; arsenic and 
arsenic compounds; asbestos; beryllium; cadmium and cadmium compounds; chromium compounds, 
hexavalent; coal gasification; coke production; hematite mining, underground, with radon exposure; 
involuntary (passive) smoking; ionizing radiation; iron and steel founding; selected nickel compounds, 
including combinations of nickel oxides and sulphides in the nickel refining industry; painters; 
crystalline silica; soot; talc containing asbestiform fibers (6). 
Using the WHO Comparative Risk Assessment (CRA) methodology, the global burden of 
occupational disease and injury resulting from 8 selected risk factors (beryllium, cadmium, chromium, 
diesel exhaust, nickel, arsenic, asbestos, silica) in the year 2000 included 850,000 deaths and 
approximately 24 million years of healthy life lost. Without correction for underestimation, these 
selected occupational risk factors alone accounted for about 1.5% of all mortality and about 1.6% of all 
Disability-Adjusted Life Years (DALYs) in the world in the year 2000. The third occupational cause of 
death was lung cancer (12%) (7). 
In Europe, assuming attributable fractions of 7-15% among men and 2-9% among women, 
29,300 and 3,200 lung cancer deaths have been estimated respectively (8). 
From the epidemiological studies conducted worldwide a great variability in the proportion of 
lung cancer cases attributable to occupational risk factors emerges, ranging from 0 to 40%, that can be 
explained with the different proportion of workers exposed to high risk occupations according to time 
and place specific industrial background (9). 
In 1990-1993 the prevalence of working population exposed to occupational carcinogens was 
still elevated: among the 140 million workers across 15 European Community countries, 32 million 
resulted exposed and 7 million to the selected 8 lung carcinogens mentioned above (10). In Italy, these 
estimates were 4 and 1 million respectively and after ten years (2000-2003) only small decreases 
emerged (11-12). 
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Genetic risk factors 
 
Even if only 2% of lung cancer cases among males and 30-50% among women have never 
smoked (13), fewer than 20% of cigarette smokers develop lung cancer (14). Global statistics estimate 
that 15% of lung cancers in men and 53% in women are not attributable to smoking, overall accounting 
for 25% of all lung cancer cases worldwide (4). Familial aggregation of lung cancer is reported (15) 
and a recent meta-analysis estimated a 1.5-fold elevated risk among never smoking probands with 
affected first degree relatives (16), suggesting that inherited genetic factors may also be important risk 
determinants. 
The research of individual genetic susceptibility for lung cancer has been supported by 
development of rather simple and rapid new techniques of molecular biology (i.e., polymerase chain 
reaction (PCR)-based assays) for DNA-sequencing that has enabled precise identification of an 
individual's genotype. 
Beyond the research on uncommon “high-penetrance” genetic mutations, able by themselves (in 
absence of other factors) to increase lung cancer susceptibility (e.g. KRAS, EGFR, Tp53), highly 
relevant are the investigations on common (frequency >1% among population) “low-penetrance” 
(increasing risk only in presence of other factors) polymorphisms. In fact, because of the broad 
occurrence of low-penetrance polymorphisms among general population, the potential impact on public 
health is pivotal for the possibility to prevent not only the cases attributable to them, but also to 
interaction with environmental factors (17). 
Six biologically plausible patterns of a simple gene-environment interaction model on the 
relative risk of disease have been proposed (18): 
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1. Type 1: the increased risk of disease is only observed when both genetic and environmental 
factors co-participate in the same pathogenic mechanism (neither the genotype alone nor the 
exposure alone causes excess risk);  
2. Type 2: the environmental exposure is associated with increased disease risk, whereas genotype 
alone is not; 
3. Type 3: the genotype is associated with increased disease risk, whereas environmental exposure 
alone is not; 
4. Type 4: both the genotype and the environmental exposure are each associated with excess risk 
of disease with a possible synergistic effect in case of co-exposure; 
   5-6. Types 5 and 6: occur when there is a reversal of the genotype's effect, depending on the 
presence or absence of environment factors: the genotype is protective in the absence of 
environmental factors, but is deleterious in the presence of the environmental factors. 
A similar, more-complex model, also considering the number of genetic loci involved and of 
environmental exposure factors, has been proposed (19). 
In occupational epidemiology the Type 2 pattern is the most studied since most occupational 
carcinogens may increase their toxicity in presence of specific metabolic polymorphisms, but the 
same genetic variants are not able by themselves to increase the risk (20). 
Several genes, potentially involved in different carcinogenesis phases, have been intensively 
studied as suitable “candidates genes” for lung cancer susceptibility, in particular those that would 
influence lung cancer risk as a result of gene-environment interaction. Genotyping analyses on lung 
cancer have been carried out on xenobiotic metabolizing enzymes with known genetic polymorphisms, 
involved in the metabolism of environmental or tobacco carcinogens, and on DNA repair enzymes, 
involved in repair of DNA damaged by endogenous and exogenous mutagens (21). 
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Variations in an individual's metabolic phenotype, have been detected in a variety of enzymes 
involved in activation (phase 1: oxidation/reduction/hydrolysis) and detoxification (phase 2: 
conjugation) of chemical carcinogens. This phenotypic metabolic variation is related to genetic 
polymorphisms (i.e., metabolic polymorphism). A growing number of genes encoding carcinogen-
metabolizing enzymes have been identified and cloned. Consequently, there is increasing knowledge of 
the allelic variants or genetic defects that give rise to the observed variation (20). 
Specifically for lung cancer the most widely studied polymorphic loci are those coding for 
phase 1 and 2 enzymes, involved respectively in the activation of polycyclic aromatic hydrocarbons 
(PAHs), N-nitrosamines, and aromatic amines and detoxification of epoxides and aromatic amines 
derived from tobacco smoke. Between them, the most frequently studied enzymes include CYP1A1, 
microsomal epoxide hydrolase 1 (mEH/EPHX1), myeloperoxidase (MPO), manganese superoxide 
dismutase (SOD2), NAD(P)H quinone oxidoreductase 1 (NQO1) and the glutathione S-transferases 
(GST) family, in particular GSTM1 and GSTT1) (22-35). 
Nevertheless, the available published data generally offer inconsistent results, likely due to 
heterogeneity of study populations, failure to consider effect modifiers such as environmental 
exposures (gene-environment interaction), poor characterization of the exposure, lack of statistical 
power causing false negatives, and multiple testing creating false-positive results, as well as publication 
bias (27, 36).  
An additional shortcoming of previous studies is that few have focused on detecting the genetic 
metabolic polymorphisms able to increase individual susceptibility for lung cancer associated with 
exposure to occupational carcinogens, and they have produced inconsistent results (37-42). 
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STUDY AIM 
 
The aim of this study is to investigate the interaction between exposures to selected 
known/suspected occupational carcinogens and phase II metabolic gene polymorphisms associated 
with lung cancer risk.  
There are several specific goals: 
1- To improve understanding of the mechanisms of action of known or suspected occupational 
carcinogens in the lung cancer carcinogenesis pathway, for theoretic-scientific purpose; 
2- To evaluate the global impact of these factors and their interaction on public health, calculated 
as population attributable fraction (PAF), that estimates the number of cases avoidable every 
year by eliminating the risk factor in the population exposed; 
3- To enable identification of susceptible subgroups of the population at higher risk, even at 
current low exposure levels.  
To achieve these aims, I have conducted a candidate gene association study with a systematic and 
integrated approach. To take into account the underlying biological complexity, I adopted a multi-
level approach that featured analyses at the single nucleotide polymorphism (SNP), gene, haplotype 
and pathway levels. In addition, I evaluated in gene expression data the correlation between the genetic 
variants found associated with occupational carcinogens and the genetic functional variants at lung 
tissue level.  
The most important potential impacts of this research would be a re-evaluation of the exposure 
threshold values that are currently in force, public health campaigns, screening interventions focused 
on susceptible subjects for primary and secondary prevention (e.g., early cancer detection among 
exposed workers during health surveillance), with obvious issues also on ethical ground (43-45), and 
recognition and compensation of occupational cancer cases. 
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EAGLE (Environment And Genetics in Lung cancer Etiology) study, born from the 
collaboration between the National Cancer Institute (NCI), Bethesda (USA) and the EPOCA research 
centre of the University of Milan (Italy), is a large population-based case-control study recently 
conducted in Lombardy region that gives a unique opportunity to achieve these aims: it was designed 
with the goal of investigating the genetic and environmental determinants of lung cancer, with 
particular attention to cigarette smoking, using an integrative approach that allows combined analysis 
of genetic, environmental, clinical, and behavioural data. Moreover, it enrolled a very high number of 
subjects, also among population controls, and collected detailed information about several important 
lung cancer determinants and a relevant number of biological samples, obtaining accurate data on 
exposure and genotype. Besides, given the homogeneous genetic background of the study base (only 
subjects born in Italy, with Italian citizenship and residence in Lombardy region) there’s a minimal 
possibility of confounding by different genetic backgrounds within ethnic groups (i.e., population 
stratification). 
 
MATERIAL AND METHODS 
 
EAGLE Study: population and data collection 
 
A detailed description of the EAGLE study has been previously published (46). Briefly, the 
study includes 2,100 incident lung cancer cases and 2,120 population controls enrolled in the period 
April 2002 to June 2005 in 216 municipalities in the Lombardy region (Northern Italy). Cases were 
subjects with primary cancer of trachea, bronchus, and lung, first diagnosed between April 2002 and 
February 2005, and admitted to 13 hospitals with catchment of greater than 80% of the lung cancer 
cases in the study area. Controls were randomly sampled from the Regional Health Services Database, 
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frequency-matched to cases by area of residence (5 classes), gender, and age (5-year categories), and 
contacted through the family physician. All enrolled subjects were Caucasian. Subjects were 35–79 
years of age at diagnosis (cases) or at sampling/enrolment for interview (controls). The study 
participation rates were 86.6% among cases and 72.4% among controls. After signing an Institutional 
Review Board-approved informed consent form, subjects underwent a computer-assisted personal 
interview (CAPI) and filled-in a self-administered questionnaire. Available data includes 
demographical characteristics, detailed smoking history, family history of lung cancer and other 
cancers, previous lung diseases, medications, diet, alcohol, attempts at quitting smoking, anxiety, 
depression, personality scores, occupations, reproductive and residential history. 
Particular attention was given to the collection of data on tobacco exposure including active 
smoking (age at initiation/cessation, number of cigarettes per day in different periods) and passive 
smoking (during childhood, at work, and at home during adulthood). 
Clinical data (stage, grade, histology, imaging and pathology reports, spirometry, and routine 
laboratory tests) were recorded. All study subjects donated a blood sample (or, rarely, a buccal rinse 
sample), which was processed to obtain cryopreserved lymphocytes, red blood cells, granulocytes, 
DNA, RNA, whole blood, buffy coat, serum, plasma, and blood cards. Lung tissue paraffin blocks and 
slides were collected from the cases that underwent surgery, biopsy or cytological examination of the 
lung tumor. Multiple fresh tumor and “non-involved” lung tissue samples, frozen in liquid nitrogen 
within 20 minutes of excision, were also collected from over 500 surgical cases. 
Epidemiological and biospecimen information has been collected respectively for 98.4% and 
97.3% of cases and 99.8% and 99.9% of controls, then anonymized and stored in a secure relational 
database. Quality control procedures were implemented to ensure data completeness and accuracy. 
Several genetic and epidemiological studies are ongoing. 
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Occupational exposure assessment  
 
For jobs held for at least six months, detailed information on lifetime work history (industry, 
job title, year of start and stop) was collected for the 1,943 cases and 2,116 controls that underwent 
CAPI. Jobs (industry and job title) were then coded, blindly with respect to case-control status, by 
occupational physicians with training and experience in epidemiology and industrial hygiene, by using 
the International Standard Industrial Classification of All Economic Activities (ISIC), Revised Edition 
2 (47), and the International Standard Classification for Occupations (ISCO), 1968 (48). 
In absence of a gold standard different approaches for occupational exposure assessment can be 
used, each with advantages and limits (49-51). In the present work I have applied a general Job-
Exposure Matrix (JEM) to estimate the individual exposure to selected occupational carcinogens. The 
JEM approach, besides being very cheap and easy to apply, allows converting each job code into the 
specific exposures entailed by it, gathering workers with common exposure irrespective of their 
occupational titles, so increasing categorization sensitivity. The important advantage is the possibility 
of evaluating the causal role of single occupational carcinogens known or suspected to be associated to 
lung cancer. The main limit is the potential non-differential misclassification due to the heterogeneity 
of the industries/occupations combinations grouped in the same exposure categories, with consequent 
underestimation of the risk effect (52-54). 
 
JEM 
The JEM used in this study is the ‘DOM-JEM’, recently developed within the SYNERGY 
project, an international pooled analysis of lung cancer case–control studies coordinated by the 
International Agency for Research on Cancer (IARC), the Institute for Prevention and Occupational 
Medicine of the German Social Accident Insurance, Institute of the Ruhr-University Bochum (IPA) and 
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the Institute for Risk Assessment Sciences at Utrecht University (IRAS) (http://synergy.iarc.fr). This 
semi-quantitative JEM was created a priori (i.e. independently from any study population) to be 
applied in community-based studies. Experts’ rating was based on intensity and probability of exposure 
(55). The JEM translates all job titles (five-digit ISCO codes) into exposure to selected agents, ranked 
as 0, 1 and 2 for no, low and high exposure, respectively. 
The six known/suspected occupational lung carcinogens included in the ‘DOM-JEM’ were 
asbestos, crystalline silica, polycyclic aromatic hydrocarbons (PAH), diesel motor exhausts 
(DME), chromium compounds (Cr) and nickel compounds (Ni). These agents had been previously 
selected for the SYNERGY project, according to the following criteria: (i) IARC evaluation: known 
(Group 1) or suspected (Group 2A/2B) lung carcinogens; (ii) relevance for recognition of occupational 
diseases associated with these agents (recognized number of cases per year by Workers Health 
Insurance); (iii) prevalence of exposure and probability of simultaneous exposures to two or more 
agents over the course of an individual job history in the general population; and (iv) available 
information for quantitative exposure assessment. I merged the five-digit ISCO codes for jobs held by 
each subject with the JEM to estimate the individual exposures. 
 
Genetic analysis 
 
Candidate gene approach 
For the genetic analysis I used a candidate gene approach to test directly the interaction of 
selected genetic polymorphisms and the occupational carcinogens included in the JEM in association 
with lung cancer risk. The main advantage of this method is that it is the most powerful in a population-
based case-control study to detect the small effect of low-penetrance genes in association with complex 
disease traits like lung cancer. Another important advantage is that it is relatively cheap and quick. The 
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major drawback is that the incomplete knowledge of the underlying biological mechanism limits the 
number of genes that can be tested to the ones for which at least some functional information is 
available (56). 
 
Candidate genes selection 
I conducted a comprehensive review of the literature available on this topic (22-35, 37-42, 57-
59) and I selected the candidate phase II metabolic genes that have been reported in association with: 
1) Lung cancer susceptibility 
2) The metabolism of the 6 occupational carcinogens included in the JEM 
3) Lung cancer risk and exposure to the 6 occupational carcinogens included in the JEM 
This is the final list of 23 candidate genes that were evaluated in this study: 
ABCG2, ALDH2, CAT, COMT, GSTA1, GSTA2 ,GSTA3, GSTA4, GSTCD, GSTM2, GSTM3, 
GSTM4, GSTM5, GSTP1, GSTT2, GSTZ1, MDR1, MPO, NAT1, NAT2, NQO1, SOD2, 
UGT1A7. 
The GSTT1 and GSTM1 genes were not included in this analysis because previously evaluated 
in the EAGLE study in a work recently published (35). 
 
SNP selection  
 
The SNP selection for the EAGLE study had been previously described (31). SNP assays were 
selected from those available at the Core Genotyping Facility (CGF) of the Division of Cancer 
Epidemiology and Genetics (National Cancer Institute), using NCI assessment of linkage 
disequilibrium (LD) (i.e., the non-random association of alleles at two or more loci) between the SNPs 
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from the International Haplotype Mapping Project (HapMap) database which contains the LD patterns 
of European, African and Asian populations and previous evidence from the literature.  
I selected 298 tagging SNPs. 
 
Gene coverage 
For all the 23 candidate genes, represented in the data by two or more SNPs, I evaluated the 
genetic coverage of the 298 selected tagging SNPs using Haploview software to estimate and visualize 
the pairwise LD, using as reference the present version of the HapMap database.  
An example of the good coverage of the selected tagging SNPs for the GSTM family genes is 
shown below (Graph 1). 
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Graph 1. Gene coverage of selected tagging SNPs for GSTM family genes in the EAGLE study 
compared to Hap Map reference dataset.  
 
 
 
SNP genotyping 
Genotyping of the selected 298 SNPs was performed on all the 4,050 EAGLE subjects with 
sufficient DNA samples, followed by quality-control procedures, and conducted at CGF of NCI using 
two types of assays: customized TaqMan® probes described at the NCI SNP500Cancer website 
(http://snp500cancer.nci.nih.gov) and standard Illumina HumanHap550v3_B BeadChips (Illumina, San 
Diego, CA, USA). The aim was to combine the specificity of the first assay with the sensitivity of the 
HapMap database 
EAGLE database 
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second in order to increase the genetic coverage. In case of duplicates between assays, the SNPs from 
TaqMan were retained for the analyses, because they were more specific for the selected genes. 
 
Gene expression data 
Data on microarray gene expression from peripheral blood lymphocytes were obtained using 
the Affymetrix GeneChip® HG-U133A v2.0, already described in detail (35). Briefly, the samples 
were processed and normalized with the Robust Multichip Average (RMA) method. All 22,277 probe 
sets based on RMA summary measures were used in the analyses. For the present study I used data 
from paired tumor (n = 51) and non-involved (n = 41) lung tissue samples from lung cancer cases and 
from peripheral whole blood of cases (n = 71) and controls (n = 76) with available data on occupational 
exposure. 
 
Statistical analysis 
 
Occupational exposure 
 
For each carcinogen, I evaluated a dichotomous exposure indicator (never/any), and an ordinal 
variable for intensity of exposure (never/low/high). Further, I analysed duration and cumulative 
exposure as the sum of the job-specific (intensity score × duration) products (with scores set to 1 and 4 
for low and high exposure, respectively). Latency was defined as time at lung cancer diagnosis or study 
enrolment since first exposure. The analyses were conducted using both categorical and continuous 
variables. For duration and cumulative exposure I defined the categories according to the quartiles of 
the exposure distribution among controls for each carcinogen. For latency I used predefined categories 
of exposure (never, 20-29, 30-39, 40-49, 50-59 and ≥60 years) to explore their impact on a broader 
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range of years since first exposure. When analysing those variables as continuous, I used the ln (1 + x) 
transformation to normalize their distribution. I evaluated co-exposure to the JEM carcinogens using 
Spearman's rank correlation coefficient (ρs).  
For each carcinogen exposure I calculated odds ratios (ORs), 95% confidence intervals (95% 
CIs) and tests for trend, using unconditional logistic regression, separately for males and females, 
taking subjects never exposed to the carcinogen as reference. All regression models included the 
following covariates: residential area (five categories); age (five-year categories); cigarette smoking 
(ever/never); pack-years (continuous, mean-centred: linear, quadratic, and cubic terms); time since 
quitting (0 for never/current smokers, 0.5, 1, 2, 5, 10, 20, ≥30 years); smoking (ever/never) of other 
types of tobacco (pipe, cigars, cigarillos); and, for each agent, co-exposure to the other carcinogens 
included in the JEM. I also adjusted for number of jobs held (1, 2, 3, 4, ≥5), since this variable was 
negatively associated with lung cancer among non-exposed subjects (Ptrend=0.014) and positively 
associated with exposure to carcinogens among controls (P <0.0001 from chi-squared test). I repeated 
selected analyses after adjusting for education (none, elementary, middle, and high school/higher 
degree) as a surrogate of socioeconomic status. 
For the exposures showing an increased OR, I calculated the carcinogen-specific and overall 
PAF by using the formula PEC × (OR – 1)/OR, where OR is the adjusted OR and PEC is the proportion 
of cases ever exposed to the carcinogen under study (60). The definition of exposure I used when 
calculating PAF estimates considers subjects unexposed to the carcinogen under study as belonging to 
the “reference” category and everyone even slightly exposed as belonging to the “exposed” category. 
Estimates of PAF when using this broad definition of “exposed” are less prone to bias from non-
differential misclassification of exposure, the form of misclassification expected with a JEM approach 
(61). I estimated ORs for the three main histological lung cancer types (adenocarcinoma, squamous 
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cell, and small cell carcinomas) and tested their homogeneity in a multinomial logistic regression 
model.  
I evaluated interactions between each carcinogen (never/any exposure) and cigarette smoking 
status (never/former/current) on the multiplicative scale, by comparing the likelihood of a logistic 
regression model containing the main effects of the carcinogen and smoking, with that of a model with 
also their interaction. As reference, I used subjects never exposed to both smoking and the specific 
carcinogen under study. In these models I did not adjust for co-exposure to the other JEM carcinogens 
to avoid too few subjects per strata.  
All P values were two-sided. Analyses were performed with Stata11 (62). Confidence limits of 
PAF were calculated with the command aflogit which implemented the formulas proposed by 
Greenland and Drescher (63). 
 
Genetic main effect 
 
Single SNP analysis  
 
The main effect of the variant genotypes on the risk of lung cancer was estimated by ORs and 
their 95% CIs using unconditional logistic regression analysis for all subjects and separately by gender. 
Homozygosity for the more frequent allele among controls was defined as the reference group (AA). I 
tested for significance using two-sided Wald tests. I evaluated the SNP effect both as continuous 
variable and as three levels categorical variable to test for linear trends. I adjusted the ORs for the 
matching variables (age, sex, and residential area) and for tobacco smoking: cumulative exposure 
(pack-years), intensity (cigarettes per day), and years since quitting, categorized according to the 
quartiles of distribution of exposure among controls. 
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In all the analyses I evaluated three models of genetic inheritance:  
1. Additive model: the risk conferred by an allele is increased r-fold for heterozygotes and 2r-fold 
for homozygotes. This model assumes a linear relationship between the number of allele copies 
and the associated trait, allowing performing test for trends.  
2. Dominant model: the risk conferred by an allele (dominant allele) is the same for 
heterozygotes and homozygotes. The comparison groups are wild-type homozygous genotypes 
vs. allele positivity (combining heterozygotes and homozygotes for the variant). 
3. Recessive model: the risk conferred by an allele (recessive allele) is present only for 
homozygotes. The comparison groups are variant homozygous genotypes vs. the rest 
(combining heterozygotes for the variant and homozygotes for the wild-type allele). 
Assuming that a SNP has genotypes of AA (“wild-type” homozygote), AB (heterozygote) and BB 
(variant homozygote), the genotypes were coded as AA=0, AB=1 and BB=2 in an additive model; 
AA=0 AB=1 and BB=1 in a dominant model; and AA=0, AB=0 and BB=1 in a recessive model.  
Also, I estimated ORs for the three main histological lung cancer types (adenocarcinoma, 
squamous cell, and small cell carcinomas) and tested their homogeneity in a multinomial logistic 
regression model as reported above for the occupational exposure analysis. 
 
SNP grouped by genes analysis  
I analysed multiple SNPs jointly to test whether the overall lung cancer risk was determined by 
the combined action of multiple SNPs within the same gene and/or of multiple genes within the same 
pathway, even if each SNP may have had only a modest effect individually.  
For these analyses I tried to increase the statistical power by excluding from the dataset the 
“redundant” SNPs, i.e., the SNPs in high LD more likely to be transmitted together and so carrying the 
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same genetic information. I estimated the LD between the diallelic SNPs among controls and I 
excluded the SNPs with r
2
 >0.80. 
For the SNP grouped analysis I used two models: 
1) SNP grouped “cumulative” analysis 
Under the assumption that the effect on lung cancer of each SNP was cumulative, I implemented the 
following logistic regression model: 
   
where k=1, …, n represents a collection of SNPs belonging to the same gene or a collection of SNPs 
belonging to genes in the same pathway (e.g. phase II, n = 23 i.e. all SNPs were grouped together). 
SNPk = 0 for the homozygote most common allele, SNPk= 1 for the heterozygote allele, and SNPk = 2 
for the homozygote minor allele. β is the regression coefficient for the cumulative number of variants  
∑  (SNPk). 
I estimated the overall risk of lung cancer (LC in the formula above) associated with each 
selected group of n SNPs by computing OR = exp (β). Note that in this model I do not assume nor infer 
a risk direction for each minor allele. This approach is powerful if minor alleles for all SNPs have 
effects in the same direction, but there may be loss of power if minor alleles for some SNPs affect lung 
cancer risk in opposite directions and their contribution to the overall risk cancels with each other.  
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2) SNP grouped “score” analysis  
For this analysis, in the same logistic model explained above, I treated the cumulative sum of the 
effect of each SNP (expressed by the regression coefficients β) within each gene as independent 
variable, as shown below: 
   
Genetic-occupational interaction 
Applying the same unconditional logistic regression model used for the main effect of genetic 
variants, I calculated ORs and 95%CIs by exposure to each occupational carcinogen (dichotomous 
variable: ever/never exposure), using as reference category the subjects with the “wild type” genetic 
variant who have never been exposed to the carcinogen under evaluation. 
Then I tested the interaction between genetic variants and exposure to occupational carcinogens 
on the multiplicative scale by using a 2-df likelihood ratio test (LRT) comparing the logistic regression 
model containing only the main effect of genetic and occupational variables and a model containing also 
their interaction effect.  
 
Multiple comparison considerations 
Given the high number of hypotheses tested in the single SNP analyses (298 tests corresponding 
to the 298 SNPs for the single SNP analysis and 23 tests when SNPs were grouped by genes), I took 
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multiple testing into account. I chose the Benjamini-Hochberg (64) procedure to calculate the False 
Discovery Rate (FDR) in preference to the more conservative Bonferroni correction (i.e. testing each of 
the individual tests at a significance level of α/n, where α is the statistical significance threshold, and n 
is the number of performed tests). 
In fact, my approach to multiple testing was “informed” by the selection strategy for the phase 
II genes selected. As previously reported in the Methods section, each of the genes included has 
substantial mechanistic and at least some population data which support an association with lung 
cancer and/or occupational carcinogens. I recognize that considering this to be a priori knowledge for 
each SNP may be open to debate, because of the heterogeneity of results in the literature and because 
most results actually refer to genes and not to specific SNPs, however it was not my aim to perform an 
explorative and totally “agnostic” analysis. 
I considered significant those results with a FDR-corrected-p-values ≤0.05. In addition, I 
referred to results with p-values between 0.01 and 0.05 as nominally significant, and considered them 
as notable when consistent across different analyses. 
 
Pathway analysis  
To take into account the complex interaction between genes involved in same biological 
function I performed a pathway analysis. I evaluated pathways that had been defined in externally 
curate databases (e.g., HuGE, KEGG, BioCarta, PID, etc.) and that have been previously evaluated in 
association with the outcome of interest (65-68). I used an approach combining gene-level P-values 
across the candidate genes included in the selected biological pathway through an adaptive rank-
truncated product (ARTP) method that uses a permutation algorithm for the evaluation of its significant 
level (69). 
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I evaluated 6 pathways: 
1. GSTM: GSTM2, GSTM3, GSTM4, GSTM5. 
2. GSTA: GSTA1, GSTA2, GSTA3, GSTA4 
3. NAT: NAT1, NAT2 
4. ANTIOXIDANT: SOD2, CAT  
5. GST: GSTM, GSTCD, GSTA, GSTP1, GSTZ1, GSTT2 
6. PHASE II METABOLISM: ALL 23 CANDIDATE GENES 
These pathways were tested for association with lung cancer among never and ever exposed to each 
occupational carcinogen. 
 
Haplotype analysis  
To take into consideration that biologically on the same chromosome at each genetic locus there 
are two haplotypes (i.e., the combination of alleles inherited, one maternally and the other paternally) I 
performed an haplotype analysis using the haplo.stats R-package that infers haplotype frequencies by 
assuming that all subjects are unrelated and that haplotypes are ambiguous (due to unknown linkage 
phase of the genetic markers). The genetic markers are assumed to be co-dominant (i.e., one-to-one 
correspondence between their genotypes and their phenotypes). Because there may be more than one 
pair of haplotypes that are consistent with the observed marker phenotypes, posterior probabilities of 
pairs of haplotypes for each subject were also computed using a "progressive insertion" algorithm 
which progressively inserts batches of loci into haplotypes of growing lengths, runs the expectation–
maximization (EM) steps, trims off pairs of haplotypes per subject when the posterior probability of the 
pair is below a specified threshold, and then continues these insertion, EM, and trimming steps until all 
loci are inserted into the haplotype. Only the haplotypes with a frequency above 0.02 were included in 
the analysis. 
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I tested in the same regression model used in the previous analysis the haplotype-carcinogen 
interaction term for each gene evaluated using the most frequent haplotype among controls as 
reference.  
 
Gene expression analysis  
Limited to the genes found significantly associated with exposure to occupational carcinogens 
for lung cancer risk to better understand the underlying biological mechanism, I estimated the effect of 
each SNP from a given gene on the expression of the same gene in the four types of tissue mentioned 
above. I evaluated the correlation between the number of genetic variations and mRNA expression 
using linear models (i.e., log2 expression = α + ß x genetic variant) adjusted for the same covariates 
included in the other analyses and computing fold changes (FC = 2
ß
) of expression between individuals 
with different genetic variants among never and ever exposed to the occupational carcinogen under 
evaluation. 
 
Statistical software 
All statistical analyses of genetic data were performed using the Rproject (version 2.10) 
statistical package (http://www.r-project.org/index.html). 
 
RESULTS 
Study base characteristics 
The frequency distributions for the main covariates among the 4,016 subjects included in the 
EAGLE study are shown in the Table 1. Of the 2,100 cases and 2,120 controls enrolled in our study, 
1,943 (92.5%) and 2,116 (99.8%) were interviewed, respectively. Two-thirds of the subjects came from 
the Milan area. Among men, controls had higher education and held more jobs than cases. About 14-
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15% of cases and 6-7% of controls had previously or newly-diagnosed primary cancer(s) other than 
lung cancer. Among cases, one-fourth of women were never smokers, versus only 2% of men. In both 
genders, current smokers were around 50% among cases and less than 30% among controls. Almost 
half of men (cases or controls) were former (quit > six months ago) smokers, compared to less than 
30% among women. The majority of lung cancers were adenocarcinomas (>50% in women). 
  
Table 1. Selected characteristics of lung cancer cases and controls with interview data available, the 
EAGLE study, Lombardy, Italy, 2002–2005. 
 Women Men 
 Cases Controls Cases Controls 
 N % N % N % N % 
Total participants enrolled 448  500  1652  1620  
Interviewed 406 100.0 499 100.0 1537 100.0 1617 100.0 
Area of residence         
  Milan 288 70.9 349 69.9 987 64.2 1089 67.3 
  Monza 24 5.9 23 4.6 109 7.1 94 5.8 
  Brescia 47 11.6 53 10.6 203 13.2 194 12.0 
  Pavia 21 5.2 37 7.4 107 7.0 92 5.7 
  Varese 26 6.4 37 7.4 131 8.5 148 9.2 
 P = 0.55 P = 0.17 
Age (years)         
  Mean (SD) 64.8 (10.1) 64.1 (10.1) 66.8 (7.9) 65.8 (8.1) 
 P = 0.32 P < 0.001 
Education level         
  None 21 5.2 24 4.8 91 5.9 66 4.1 
  Elementary 128 31.5 143 28.7 625 40.7 431 26.7 
  Middle 134 33.0 158 31.7 424 27.6 455 28.1 
  High 104 25.6 135 27.1 314 20.4 441 27.3 
  University 19 4.7 39 7.8 83 5.4 224 13.9 
 P = 0.35 P < 0.001 
Number of jobs         
  1 166 40.9 168 33.7 375 24.4 370 22.9 
  2 96 23.7 158 31.7 404 26.3 356 22.0 
  3 77 19.0 82 16.4 305 19.8 356 22.0 
  4 30 7.4 49 9.8 194 12.6 226 14.0 
  5+ 37 9.1 42 8.4 259 16.9 309 19.1 
 P = 0.03 P = 0.02 
Cigarette smoking         
  Never 103 25.4 282 56.5 29 1.9 397 24.6 
  Former (quit >6 months ago) 116 28.6 110 22.0 723 47.0 799 49.4 
  Current 187 46.1 107 21.4 785 51.1 420 26.0 
  Unknown 0 0.0 0 0.0 0 0.0 1 0.1 
 P < 0.001 P < 0.001 
Cigarette pack-years         
Mean (SD) 24.3 (23.1) 7.2 (13.5) 50.9 (28.7) 22.1 (23.2) 
 P < 0.001 P < 0.001 
Other cancer(s)
c
         
  No 336 82.8 448 89.8 1306 85.0 1473 91.1 
  Yes 70 17.2 51 10.2 231 15.0 144 8.9 
 P = 0.002 P < 0.001 
Lung cancer morphology         
 Adenocarcinoma 220 54.2     582 37.9     
 Squamous cell carcinoma 45 11.1     459 29.9     
 Large cell carcinoma 28 6.9     61 4.0     
 Non-small cell carcinoma NOS 34 8.4     142 9.2     
 Small cell carcinoma 38 9.4     157 10.2     
 Others 26 6.4     65 4.2     
 Not available 15 3.7     71 4.6     
   P < 0.001     
Abbreviations: EAGLE, Environment And Genetics in Lung cancer Etiology; NOS, not otherwise specified; SD, standard 
deviation. 
a
P values were derived from the χ2 test (categorical variables) or Student’s t test (continuous variables) between 
cases and controls. 
b
Percentages may not add to 100.0 because of rounding. 
c
Primary cancer(s) (previously or newly 
diagnosed) other than lung cancer. 
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Occupational exposure  
The results of the occupational exposure analysis have been recently published (70) and 
presented as a talk at the 22
nd
 International Conference on Epidemiology in Occupational Health 
(EPICOH) in Oxford, UK, September 7
th
, 2011. 
Briefly, men were most commonly exposed to asbestos (41.1% among cases and 32.2% among 
controls) and DME (38.8% among cases and 38.5% among controls). Intensity levels for the majority 
of exposed subjects were low.  
In the regression model adjusted for area, age, cigarette smoking, other types of tobacco and 
number of jobs held, we found increased ORs for lung cancer for any and even low exposure to 
asbestos, silica and Ni–Cr, with positive trends for intensity of exposure. For PAH, only subjects with 
high exposure had an increased risk. After adjusting also for co-exposure to the other JEM carcinogens, 
the estimates for associations tended to decrease for all carcinogens, in particular for high exposure to 
asbestos, low exposure to Ni–Cr and high exposure to PAH. No association was found for DME.  
The PAFs for any exposure to asbestos, silica and Ni–Cr were 18.1%, 5.7%, and 7.0%, 
respectively, corresponding to an overall PAF of 22.5% (95% CI: 14.1–30.0) (Table 2). 
  
Table 2.  Lung cancer risk for exposure to the six job–exposure matrix carcinogens for men in the 
EAGLE study, Lombardy, Italy, 2002-2005.
a
 
 Cases  Controls  ORb 95%CI ORc 95%CI PAF
d
 95%CI 
 N % N %     %  
Asbestos           
  Never
e
 905 58.9 1097 67.8 1.00  1.00    
  Any 
632 41.1 520 32.2 1.73 
1.43, 
2.09 
1.78 1.46, 2.18 
18.1 12.6, 23.3 
    Low 546 35.5 448 27.7 1.68 1.38, 
2.04 
1.76 1.42, 2.18   
    High 86 5.6 72 4.5 2.09 1.39, 
3.13 
1.51 0.94, 2.44   
     P < 0.001  P < 0.001    
Silica           
  Never
e
 1166 75.9 1363 84.3 1.00  1.00    
  Any 
371 24.1 254 15.7 1.38 
1.10, 
1.72 
1.31 1.02, 1.68 
5.7 0.4, 10.6 
    Low 328 21.3 226 14.0 1.37 1.09, 
1.73 
1.31 1.00, 1.71   
    High 43 2.8 28 1.7 1.46 0.81, 
2.61 
1.41 0.77, 2.55   
     P = 0.006  P = 0.02    
Ni-Cr           
  Never
e
 1041 67.7 1216 75.2 1.00  1.00    
  Any 
496 32.3 401 24.8 1.41 
1.16, 
1.72 
1.28 1.00, 1.63 
7.0 0.2, 13.3 
    Low 370 24.1 328 20.3 1.33 1.08, 
1.65 
1.18 0.90, 1.53   
    High 126 8.2 73 4.5 1.77 1.22, 
2.56 
1.31 0.86, 1.97   
     P < 0.001  P = 0.06    
PAH           
  Never
e
 1137 74.0 1235 76.4 1.00  1.00    
  Any 
400 26.0 382 23.6 1.11 
0.90, 
1.36 
0.87 0.68, 1.10 
  
    Low 284 18.5 321 19.9 0.90 0.72, 
1.13 
0.78 0.61, 1.00   
    High 116 7.5 61 3.7 2.46 1.65, 
3.67 
1.64 0.99, 2.70   
     P = 0.007  P = 0.75    
DME           
  Never
e
 940 61.2 994 61.5 1.00  1.00    
  Any 
597 38.8 623 38.5 0.90 
0.75 , 
1.09 
0.82 
0.67 , 
1.00 
  
    Low 476 31.0 500 30.9 0.89 0.73 , 
1.09 
0.85 0.69 , 
1.05 
  
    High 121 7.8 123 7.6 0.96 0.68 , 
1.35 
0.70 0.48 , 
1.00 
  
     P = 0.44  P = 0.047    
Abbreviations: CI, confidence interval; DME, diesel motor exhausts; EAGLE, Environment And Genetics in Lung cancer 
Etiology; Ni-Cr, nickel and chromium compounds; OR, odds ratio; PAF, population attributable fraction, PAH, polycyclic 
aromatic hydrocarbons. 
a
P values were calculated from test for linear trend for never/low/high exposure. 
b
OR calculated 
with unconditional logistic regression models, adjusted for area, age, smoking, and number of jobs. 
c
OR adjusted as 
b
 and 
also for co-exposure to the other job–exposure matrix carcinogens. dPAF calculated for any exposure to each carcinogen 
associated to an increased risk using 
c 
OR and % of cases exposed to each carcinogen. 
e
Reference category: never exposed 
to the specific carcinogen. 
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Given that asbestos was the carcinogen with the highest impact in our study in terms of both 
prevalence of exposure and strength of association with lung cancer risk, I decided to test the 
interaction between the 23 selected candidate genes and asbestos exposure only in this study. The other 
five carcinogens included in the JEM will be evaluated in future studies. 
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Genetic analysis 
SNP analysis  
Among the 298 SNPs (19 from TaqMan assay and 279 from GWAS chip) tagging 23 phase II 
metabolic genes potentially involved in asbestos detoxification process, I found 5 duplicates between 
the assays: rs7483 (GSTM3), rs1001179 (CAT), rs1695 (GSTP1), rs1138272 (GSTP1), and rs4680 
(COMT). I chose the SNPs genotyped with the TaqMan assay, as stated in the Methods section, so the 
final number of SNPs evaluated was reduced to 293.  
All analyses were restricted to the 3,899 subjects with at least a 90% genotype call rate. All 293 
SNPs passed the test for Hardy-Weinberg equilibrium genotype proportions among the 2,041 controls, 
with a p-value of 0.05 as the threshold. 
The frequency of subjects in the EAGLE study with genotype and asbestos exposure data 
available are shown in the Table 3: The four tagging SNPs for the GSTM4 gene are shown as an 
example.  
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Table 3. Frequency of subjects with genotype and asbestos exposure (ever/never) data available, in the 
EAGLE study, Lombardy, Italy, 2002-2005. The four tagging SNPs for the GSTM4 gene are reported 
as an example.  
GSTM4 
SNP Name 
Genotype 
 
Controls 
 
Cases 
 
Controls 
Never Exposed 
Controls 
Ever Exposed 
Cases 
Never Exposed 
Cases 
Ever Exposed 
rs12745189  
  
SNP = 0 553 540 403 150 325 181 
SNP = 1 991 913 727 261 554 303 
SNP = 2 434 464 308 125 290 147 
SNP = NA 142 183 108 34 96 47 
rs668413  
  
SNP = 0 734 717 522 209 458 209 
SNP = 1 955 889 698 256 536 307 
SNP = 2 290 314 218 72 176 117 
SNP = NA 141 180 108 33 95 45 
rs560018  
  
SNP = 0 890 855 633 254 541 257 
SNP = 1 858 824 638 219 492 288 
SNP = 2 217 223 155 62 124 84 
SNP = NA 155 198 120 35 108 49 
rs650985  
  
SNP = 0 1798 1780 1311 484 1075 600 
SNP = 1 177 136 123 53 91 33 
SNP = 2 3 3 3 0 3 0 
SNP = NA 142 181 109 33 96 45 
Abbreviations: NA = Not Available. 
SNP has genotypes coded as 0 for “wild-type” homozygote, 1 for heterozygote, and 2 for variant homozygote. 
 
Given the large amount of test performed in the following tables I have reported the results only 
for the SNPs found nominally (in italics) or statistically (in bold) associated with asbestos exposure for 
lung cancer risk. Both raw and FDR corrected p-values are reported.  
 
All subjects: Considering an additive model, the SNPs rs668413 and rs560018 tagging the 
GSTM4 gene showed a null effect among never exposed to asbestos, and an increase risk among ever 
exposed with a positive trend per allele copy (ptrend values=0.002 and 0.006, respectively). The LRT p-
values for interaction with asbestos exposure (pinteraction values =0.004 and 0.015, respectively) did not 
remained statistically significant after the FDR correction for multiple comparison (Table 4). 
 
  
Table 4. ORs and 95% CIs of lung cancer for SNPs by never/ever asbestos exposure for significant (bold) or nominally significant 
(italics) SNP-asbestos interactions in the EAGLE study, Lombardy, Italy, 2002-2005. All subjects. 
Gene  SNP Name  Comparison  
Co 
Nev 
Asb  
Ca 
Nev 
Asb  
Nev 
 OR  
Nev
CI1  
Nev
CI2  
Nev  
 p-
value  
Co 
Ever 
Asb  
Ca 
Ever 
Asb  
Ever 
OR  
Ever 
CI1  
Ever 
CI2  
Ever 
p-
value  
LRT 
  p-
value  
LRT 
FDR  
p-
value  
up GSTM4  rs12745189  1) Trend  403  325  1.04  0.92  1.19  0.523  150  181  0.95  0.78  1.15  0.587  0.419  0.909  
up GSTM4  rs12745189  2) AA=0, AB=1  727  554  0.88  0.71  1.10  0.259  261  303  0.86  0.63  1.19  0.368  0.660  0.920  
up GSTM4  rs12745189  3) AA=0, BB=1  308  290  1.10  0.85  1.43  0.448  125  147  0.91  0.62  1.33  0.627  NA  NA 
up GSTM4  rs12745189  4) AA=0, AB+BB=1  1035  844  0.95  0.77  1.16  0.611  386  450  0.88  0.65  1.19  0.396  0.676  0.997  
up GSTM4  rs12745189  5) AA+AB=0, BB=1  308  290  1.20  0.96  1.48  0.105  125  147  1.00  0.72  1.38  0.991  0.362  0.882  
up GSTM4  rs668413  1) Trend  522  458  0.96  0.84  1.10  0.568  209  209  1.36  1.12  1.66  0.002  0.004  0.625  
up GSTM4  rs668413  2) AA=0, AB=1  698  536  0.85  0.7  1.04  0.106  256  307  1.26  0.93  1.70  0.135  0.016  0.598  
up GSTM4  rs668413  3) AA=0, BB=1  218  176  1.00  0.75  1.31  0.977  72  117  1.93  1.28  2.93  0.002  NA  NA  
up GSTM4  rs668413  4) AA=0, AB+BB=1  916  712  0.88  0.73  1.06  0.190  328  424  1.40  1.05  1.85  0.020  0.008  0.751  
up GSTM4  rs668413  5) AA+AB=0, BB=1  218  176  1.09  0.85  1.41  0.504  72  117  1.70  1.16  2.48  0.006  0.056  0.730  
GSTM4  rs560018  1) Trend  633  541  0.98  0.85  1.12  0.749  254  257  1.32  1.08  1.62  0.006  0.015  0.874  
GSTM4  rs560018  2) AA=0, AB=1  638  492  0.89  0.73  1.08  0.233  219  288  1.52  1.13  2.03  0.005  0.010  0.590  
GSTM4  rs560018  3) AA=0, BB=1  155  124  1.06  0.78  1.44  0.727  62  84  1.55  1.00  2.42  0.051  NA  NA  
GSTM4  rs560018  4) AA=0, AB+BB=1  793  616  0.92  0.77  1.11  0.374  281  372  1.52  1.16  2.01  0.003  0.003  0.751  
GSTM4  rs560018  5) AA+AB=0, BB=1  155  124  1.12  0.83  1.5  0.456  62  84  1.27  0.83  1.92  0.271  0.638  0.968  
  
Table4.(Continued) 
Gene  SNP Name  Comparison  
Co 
Nev 
Asb  
Ca 
Nev 
Asb  
Nev 
OR  
Nev 
CI1  
Nev 
CI2  
Nev  
 p-
value  
Co 
Ever 
Asb  
Ca 
Ever 
Asb  
Ever 
OR  
Ever 
CI1  
Ever 
CI2  
Ever 
p-
value  
LRT 
  p-
value  
LRT 
FDR  
p-
value  
GSTM4  rs650985  1) Trend  1311  1075  1.04  0.76  1.43  0.804  484  600  0.46  0.27  0.77  0.003  0.008  0.754  
GSTM4  rs650985  2) AA=0, AB=1  123  91  NA  NA  NA  NA  53  33  NA  NA  NA  NA  NA  NA  
GSTM4  rs650985  3) AA=0, BB=1  3  3  NA  NA  NA  NA  NA  NA  NA  NA  NA  NA  NA   NA  
GSTM4  rs650985  4) AA=0, AB+BB=1  126  94  1.02  0.73  1.42  0.908  NA  NA  0.46  0.27  0.77  0.003  0.010  0.751  
GSTM4  rs650985  5) AA+AB=0, BB=1  3  3  2.30  0.34  15.52  0.394  NA  NA  2.30  0.34  15.52  0.394  NA  NA  
Abbreviations: Ca, cases; CI1, lower confidence interval; CI2, upper confidence interval; Co, controls; EAGLE, Environment And Genetics in Lung cancer Etiology; 
OR, odds ratio; NA, not available; NevAsb, never exposed to asbestos. 
ORs calculated with unconditional logistic regression models, adjusted for the matching variables (age, sex, and residential area) and for tobacco smoking: cumulative 
exposure (pack-years), intensity (cigarettes per day), and years since quitting, categorized according to the quartiles of distribution of exposure among controls.  
Comparison: 1) Test for trend; 2) - 3) Additive model; 4) Dominant model; 5) Recessive model. 
Pinteraction values were calculated from 2-df log-likelihood ratio tests (LRT) between the model with and without interaction term for joint exposure to the genetic variant 
(SNP: 0,1, 2 variant) and asbestos (never/any exposure). Both row and FDR corrected LRT p-values are reported. 
Reference category: never exposed to both the genetic variant and asbestos. 
 
 
Men: The nominally significant interaction with asbestos exposure among all subjects for the two SNPs tagging the GSTM4 gene 
was confirmed among men again in an additive model. Of note, in a recessive model the SNP rs668163 tagging the GSTA3 gene showed 
a borderline statistically significant interaction (FDR-corrected LRT p value = 0.102) with asbestos exposure (Table 5). 
  
Table 5. ORs and 95% CIs of lung cancer for SNPs by never/ever asbestos exposure for significant (bold) or nominally significant 
(italics) SNP-asbestos interactions in the EAGLE study, Lombardy, Italy, 2002-2005. Men only. 
Gene  
SNP 
Name  
Comparison  
Co 
NevAsb  
Ca 
NevAsb  
Never 
OR  
Never 
CI1  
Never 
CI2  
Never  
p-value  
Co 
 Ever  
Ca  
Ever  
Ever 
OR  
Ever 
CI1  
Ever 
CI2  
Ever  
p-value  
LRT 
 p-
value  
LRT 
FDR  
p-value  
up GSTM4  rs668413  1) Trend  360  316  0.97  0.83  1.14  0.739  186  204  1.29  1.05  1.59  0.015  0.033  0.909  
up GSTM4  rs668413  2) AA=0, AB=1  501  398  0.88  0.69  1.12  0.307  237  277  1.08  0.79  1.49  0.624  0.097  0.888  
up GSTM4  rs668413  3) AA=0, BB=1  161  124  1.00  0.71  1.40  0.995  67  110  1.83  1.19  2.84  0.006       NA    NA  
up GSTM4  rs668413  4) AA=0, AB+BB=1  662  522  0.91  0.72  1.14  0.413  304  387  1.24  0.92  1.67  0.165  0.109  0.969  
up GSTM4  rs668413  5) AA+AB=0, BB=1  161  124  1.08  0.79  1.46  0.644  67  110  1.75  1.18  2.61  0.006  0.056  0.768  
GSTM4  rs560018  1) Trend  432  376  0.99  0.84  1.17  0.885  230  246  1.30  1.05  1.61  0.015  0.045  0.909  
GSTM4  rs560018  2) AA=0, AB=1  472  361  0.88  0.7  1.11  0.288  201  263  1.40  1.03  1.91  0.031  0.056  0.888  
GSTM4  rs560018  3) AA=0, BB=1  110  89  1.11  0.76  1.62  0.602  58  78  1.59  1.00  2.53  0.051       NA   NA   
GSTM4  rs560018  4) AA=0, AB+BB=1  582  450  0.92  0.74  1.15  0.462  259  341  1.44  1.08  1.93  0.013  0.016  0.969  
GSTM4  rs560018  5) AA+AB=0, BB=1  110  89  1.18  0.82  1.69  0.374  58  78  1.34  0.87  2.08  0.188  0.653  0.920  
up GSTA3  rs668163  1) Trend  411  355  0.96  0.82  1.13  0.601  213  249  1.23  0.99  1.52  0.060  0.068  0.909  
up GSTA3  rs668163  2) AA=0, AB=1  464  380  1.05  0.83  1.34  0.661  231  256  0.88  0.65  1.20  0.427  0.002  0.241  
up GSTA3  rs668163  3) AA=0, BB=1  147  103  0.85  0.6  1.21  0.376  46  86  2.11  1.29  3.45  0.003       NA   NA   
up GSTA3  rs668163  4) AA=0, AB+BB=1  611  483  1.00  0.8  1.25  0.973  277  342  1.05  0.79  1.4  0.743  0.810  0.984  
up GSTA3  rs668163  5) AA+AB=0, BB=1  147  103  0.83  0.6  1.15  0.267  46  86  2.24  1.41  3.58  0.001  0.001  0.102  
up GSTA3  rs9296695  1) Trend  858  727  0.81  0.6  1.10  0.177  413  505  1.06  0.72  1.55  0.768  0.285  0.911  
up GSTA3  rs9296695  2) AA=0, AB=1  151  106  0.83  0.6  1.15  0.273  72  76  0.84  0.55  1.27  0.400  0.053  0.888  
up GSTA3  rs9296695  3) AA=0, BB=1  7  3  0.44  0.08  2.4  0.342  2  7  8.53  1.41  51.77  0.020       NA   NA    
up GSTA3  rs9296695  4) AA=0, AB+BB=1  158  109  0.82  0.6  1.12  0.215  74  83  0.94  0.62  1.42  0.768  0.600  0.984  
up GSTA3  rs9296695  5) AA+AB=0, BB=1  7  3  0.45  0.08  2.46  0.356  2  7  8.77  1.45  53.15  0.018  0.015  0.624  
Abbreviations: Ca, cases; CI1, lower confidence interval; CI2, upper confidence interval; Co, controls; EAGLE, Environment And Genetics in Lung cancer Etiology; 
OR, odds ratio; NA, not available; NevAsb, never exposed to asbestos. 
ORs calculated with unconditional logistic regression models, adjusted for the matching variables (age, and residential area) and for tobacco smoking: cumulative 
exposure (pack-years), intensity (cigarettes per day), and years since quitting, categorized according to the quartiles of distribution of exposure among controls.  
Comparison: 1) Test for trend; 2) - 3) Additive model; 4) Dominant model; 5) Recessive model. 
Pinteraction values were calculated from 2-df log-likelihood ratio tests (LRT) between the model with and without interaction term for joint exposure to the genetic variant 
(SNP: 0,1, 2 variant) and asbestos (never/any exposure). Both row and FDR corrected LRT p-values are reported. Reference category: never exposed to both the 
genetic variant and asbestos. 
  
Women: The SNP rs668413 tagging GSTM4 showed a borderline statistically significant 
interaction with asbestos exposure in a dominant model (FDR-LRT p-value = 0. 065), and a nominally 
significant interaction in the additive model (LRT p-value = 0.008). In the same gene, the SNP 
rs12745189 showed a statistically significant interaction with asbestos exposure in a recessive model 
(FDR-LRT p value = 0.013). In addition, SNPs tagging GSTM3 (rs4970774) and SOD2 (sod2_05) 
genes showed in an additive model a borderline interaction (FDR-p value ~10%) with asbestos 
exposure. It is important to underline that the few women exposed to asbestos rendered these estimates 
instable (Table 6). 
  
Table 6. ORs and 95% CIs of lung cancer for SNPs by never/ever asbestos exposure for significant (bold) or nominally significant 
(italics) SNP-asbestos interactions in the EAGLE study, Lombardy, Italy, 2002-2005. Women only. 
Gene 
  
SNP Name 
  
Comparison 
  
Co 
NevAsb  
Ca 
NevAsb  
Nev  
OR  
Nev 
CI1  
Nev 
CI2  
Nev  
p-value  
Co Ever 
Asb  
Ca Ever 
Asb  
Ever 
OR  
Ever 
CI1  
Ever 
CI2  
Ever  
p-value  
LRT  
p-value  
LRT 
FDR  
p-value  
up GSTM4  rs12745189  1) Trend  114  87  1.09  0.87  1.36  0.463  14  14  0.47  0.23  0.96  0.037  0.024  0.375  
up GSTM4  rs12745189  2) AA=0, AB=1  206  153  0.96  0.65  1.43  0.851  17  26  2.06  0.67  6.29  0.206  0.000  0.031  
up GSTM4  rs12745189  3) AA=0, BB=1  96  92  1.19  0.76  1.88  0.446  16  2  0.09  0.01  0.58  0.011           NA  NA  
up GSTM4  rs12745189  4) AA=0, AB+BB=1  302  245  1.04  0.72  1.50  0.848  33  28  0.99  0.35  2.84  0.990  0.940  0.983  
up GSTM4  rs12745189  5) AA+AB=0, BB=1  96  92  1.22  0.84  1.78  0.302  16  2  0.06  0.01  0.32  0.001  0.000  0.013  
up GSTM4  rs668413  1) Trend  162  142  0.97  0.77  1.22  0.779  23  5  2.99  1.30  6.85  0.010  0.008  0.205  
up GSTM4  rs668413  2) AA=0, AB=1  197  138  0.80  0.56  1.14  0.218  19  30  8.71  2.48  30.61  0.001  0.001  0.075  
up GSTM4  rs668413  3) AA=0, BB=1  57  52  1.04  0.64  1.71  0.867  5  7  5.13  0.9  29.15  0.065           NA  NA  
up GSTM4  rs668413  4) AA=0, AB+BB=1  254  190  0.86  0.61  1.20  0.362  24  37  7.94  2.33  27.08  0.001  0.000  0.065  
up GSTM4  rs668413  5) AA+AB=0, BB=1  57  52  1.18  0.74  1.86  0.485  5  7  1.19  0.28  5.08  0.816  0.990  1.000  
GSTM4  rs560018  1) Trend  201  165  0.99  0.78  1.26  0.919  24  11  1.71  0.77  3.80  0.187  0.190  0.731  
GSTM4  rs560018  2) AA=0, AB=1  166  131  0.95  0.67  1.36  0.795  18  25  3.40  1.18  9.78  0.023  0.065  0.583  
GSTM4  rs560018  3) AA=0, BB=1  45  35  1.00  0.58  1.73  0.991  4  6  1.24  0.22  6.92  0.809         NA  
 GSTM4  rs560018  4) AA=0, AB+BB=1  211  166  0.97  0.70  1.34  0.836  22  31  2.90  1.04  8.07  0.041  0.042  0.454  
GSTM4  rs560018  5) AA+AB=0, BB=1  45  35  1.03  0.61  1.73  0.918  4  6  0.62  0.13  3.08  0.560  0.562  0.939  
up GSTM3  rs4970774  1) Trend  119  99  0.93  0.74  1.17  0.530  16  9  2.96  1.49  5.86  0.002  0.001  0.128  
up GSTM3  rs4970774  2) AA=0, AB=1  198  163  0.99  0.67  1.45  0.940  23  20  3.50  1.08  11.33  0.036  0.006  0.203  
up GSTM3  rs4970774  3) AA=0, BB=1  98  69  0.85  0.53  1.37  0.509  8  13  8.71  2.22  34.28  0.002         NA  NA  
up GSTM3  rs4970774  4) AA=0, AB+BB=1  296  232  0.94  0.66  1.36  0.754  31  33  4.71  1.56  14.24  0.006  0.006  0.189  
up GSTM3  rs4970774  5) AA+AB=0, BB=1  98  69  0.86  0.58  1.28  0.465  8  13  3.89  1.26  12.02  0.018  0.013  0.618  
up SOD2  rs4342445  1) Trend  222  194  0.96  0.73  1.25  0.739  28  18  2.33  0.92  5.9  0.075  0.066  0.545  
up SOD2  rs4342445  2) AA=0, AB=1  163  117  0.87  0.62  1.24  0.451  18  23  3.16  1.19  8.42  0.021  0.035  0.454  
up SOD2  rs4342445  3) AA=0, BB=1  31  21  1.07  0.56  2.06  0.843  1  1  0.53  0.03  9.92  0.670           NA  NA  
up SOD2  rs4342445  4) AA=0, AB+BB=1  194  138  0.9  0.65  1.26  0.551  19  24  2.91  1.10  7.66  0.031  0.024  0.350  
up SOD2  rs4342445  5) AA+AB=0, BB=1  31  21  1.13  0.59  2.14  0.713  1  1  0.31  0.02  5.56  0.425  0.403  0.939  
SOD2  rs2758331  1) Trend  114  97  0.97  0.77  1.22  0.792  10  15  0.36  0.17  0.75  0.007  0.010  0.226  
SOD2  rs2758331  2) AA=0, AB=1  206  155  0.83  0.56  1.22  0.344  25  23  0.41  0.13  1.23  0.111  0.033  0.454  
SOD2  rs2758331  3) AA=0, BB=1  96  80  0.95  0.60  1.51  0.840  12  4  0.12  0.03  0.57  0.008           NA  NA  
SOD2  rs2758331  4) AA=0, AB+BB=1  302  235  0.87  0.60  1.25  0.444  37  27  0.31  0.11  0.88  0.028  0.067  0.524  
SOD2  rs2758331  5) AA+AB=0, BB=1  96  80  1.07  0.73  1.58  0.719  12  4  0.21  0.05  0.85  0.029  0.021  0.618  
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Table 6.(Continued) 
SOD2  sod2_05  1) Trend  103  90  0.99  0.79  1.24  0.911  13  6  3.47  1.66  7.28  0.001  0.001  0.128  
SOD2  sod2_05  2) AA=0, AB=1  216  160  0.84  0.56  1.25  0.384  29  23  3.04  0.82  11.24  0.096  0.005  0.203  
SOD2  sod2_05  3) AA=0, BB=1  113  91  0.97  0.62  1.53  0.900  8  16  11.72  2.63  52.12  0.001           NA  NA  
SOD2  sod2_05  4) AA=0, AB+BB=1  329  251  0.88  0.61  1.28  0.509  37  39  4.59  1.3  16.18  0.018  0.011  0.267  
SOD2  sod2_05  5) AA+AB=0, BB=1  113  91  1.09  0.76  1.58  0.639  8  16  5.08  1.7  15.18  0.004  0.008  0.618  
Abbreviations: Ca, cases; CI1, lower confidence interval; CI2, upper confidence interval; Co, controls; EAGLE, Environment And Genetics in Lung cancer Etiology; 
OR, odds ratio; NA, not available; NevAsb, never exposed to asbestos. 
ORs calculated with unconditional logistic regression models, adjusted for the matching variables (age, and residential area) and for tobacco smoking: cumulative 
exposure (pack-years), intensity (cigarettes per day), and years since quitting, categorized according to the quartiles of distribution of exposure among controls.  
Comparison: 1) Test for trend; 2) - 3) Additive model; 4) Dominant model; 5) Recessive model. 
Pinteraction values were calculated from 2-df log-likelihood ratio tests (LRT) between the model with and without interaction term for joint exposure to the genetic variant 
(SNP: 0,1, 2 variant) and asbestos (never/any exposure). Both row and FDR corrected LRT p-values are reported. Reference category: never exposed to both the 
genetic variant and asbestos. 
 
Analyses by the major histology types: Restricted to adenocarcinoma, squamous carcinoma and small cell carcinoma cases a 
few SNP-asbestos interactions were found. After the correction with FDR method none of them was confirmed. Of note, among 
adenocarcinoma cases, the most frequent histology in our study base, using an additive model the best LRT p-value between ever and 
never exposed to asbestos for ptrend values was again for the SNP rs650985 tagging the GSTM4 gene (LRT p-value = 0.005) (Data not 
shown). 
SNP grouped by genes analysis 
In the grouped SNP analyses to increase the detection power I excluded the SNPs in strong LD as stated in the Methods. I 
measured the association between the allele pairs as r
2
 correlation coefficients and represented them on a genetic map using the 
LDheatmap R-package (Graph 2). A few SNPs were eliminated from the analysis. Table 7 shows the paired LD among the four SNPs 
covering the GSTM4 gene as an example: no strong LD (r
2
<0.80) has resulted.  
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Table 7. Paired LD in r
2
 among the four SNPs tagging the GSTM4 gene. 
  rs12745189 rs668413 rs560018 rs650985 
rs12745189 1.00 0.57 0.42 0.04 
rs668413   1.00 0.74 0.03 
rs560018     1.00 0.02 
rs650985       1.00 
 
Graph 2. Genetic map showing the association on a grey colour scale between the four SNPs tagging the GSTM4 gene. 
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SNP grouped by genes “cumulative” analysis 
Among all subjects I confirmed the interaction nominally significant between the SNPs tagging GSTM4 gene and asbestos 
exposure (LRT p-value =0.006). Also, I found a cumulative effect with a positive trend for number of variants within the gene (ptrend 
value=0.014) that did not remain significant after the FDR correction (Table 8). 
  
Table 8. ORs and 95%CIs of lung cancer for grouped SNP “cumulative” effect tagging GSTM4 gene by never/ever asbestos exposure 
and LRT p –values of interaction, in the EAGLE study, Lombardy, Italy, 2002-2005. All subjects. 
   Co  Ca  OR  CI1  CI2  p-val  
Co  
Nev  
Ca 
 Nev  
OR 
 Nev  
CI1 
 Nev  
CI2 
 Nev  
p-val  
Nev  
Co 
Ever  
Ca 
Ever  
OR 
Ever  
CI1 
Ever  
CI2 
Ever  
p-val 
Ever  
LRT  
p-
value  
LRT 
FDR  
p-
value  
GSTM4 
N. SNPs 
                                                            
0  19  14  1.09 0.995  1.184  0.063  12  9  1.00 0.897  1.109  0.994  7  4  1.31 1.113  1.532  0.002  
  
1  220  196  1.10 0.479  2.535  0.819  159  130  1.15 0.412  3.206  0.791  60  50  0.94 0.215  4.123  0.936  
  
2  770  757  1.31 0.581  2.932  0.518  548  476  1.30 0.477  3.523  0.611  220  236  1.32 0.316  5.481  0.705  0.006  0.137  
3  737  701  1.29 0.575  2.903  0.535  551  410  1.07 0.394  2.910  0.894  185  251  1.94 0.465  8.072  0.364  
  
4  217  230  1.56 0.679  3.570  0.296  155  130  1.38 0.495  3.856  0.538  62  86  1.94 0.450  8.387  0.373  
  
P trend  
                  
0.014  0.347  
Abbreviations: Ca, cases; CI1, lower confidence interval; CI2, upper confidence interval; Co, controls; EAGLE, Environment And Genetics in Lung cancer Etiology; 
OR, odds ratio; N., number; Nev, never exposed to asbestos. 
ORs calculated with unconditional logistic regression models, adjusted for the matching variables (age, sex, and residential area) and for tobacco smoking: cumulative 
exposure (pack-years), intensity (cigarettes per day), and years since quitting, categorized according to the quartiles of distribution of exposure among controls.  
Pinteraction values were calculated from 2-df log-likelihood ratio tests between the model with and without interaction term for joint exposure to the genetic variant (SNP: 
0,1, 2 variant) and asbestos (never/any exposure). P trend for number of genetic variants within gene. Both row and FDR corrected p-values are reported. 
Reference category: never exposed to both the genetic variant and asbestos. 
 
Not significant association were found in the subgroup analyses by gender and histology (data not shown). 
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SNP grouped by genes “score” analysis 
Among all subjects I confirmed the interaction between the SNP group tagging GSTM4 gene and asbestos exposure. In specific, 
the score, that I created to take into account both the number and the effect (expressed by the regression coefficient β) of each variant 
within the gene, resulted significantly associated with asbestos for lung cancer risk even after the FDR correction (p-value <0.000) (Table 
9). 
  
Table 9. ORs and 95%CIs of lung cancer for grouped SNP “score” for all 23 genes by never/ever asbestos exposure and corresponding 
LRT p-values of interaction, in the EAGLE study, Lombardy, Italy, 2002-2005. All subjects. 
SNP Group  N SNP  Co Nev  
 Asb  
Ca Nev  
 Asb  
Co Ever  
Asb  
Ca Ever 
 Asb  
LRT  LRT 
Nev Asb  
LRT  
Ever Asb  
LRT 
P- value  
LRT  
FDR p-value  
GSTM4  4  1425  1155  534  627  0.257  0.930  <0.001  <0.001  <0.001  
GSTM2  3  1436  1169  537  633  0.746  0.359  0.402  0.154  0.600  
GSTM5  5  1426  1161  533  630  0.694  0.759  0.425  0.497  0.761  
GSTM3  13  1372  1104  519  594  0.119  0.668  0.314  0.384  0.679  
UGT1A7  39  1295  1050  492  565  0.175  0.127  0.750  0.196  0.600  
ABCG2  20  1414  1147  530  622  0.958  0.726  0.686  0.853  0.902  
GSTCD  18  1394  1148  524  617  0.272  0.166  0.755  0.382  0.679  
GSTA2  3  1427  1160  532  626  0.775  0.865  0.145  0.081  0.600  
GSTA1  4  1389  1127  523  612  0.017  0.241  0.024  0.273  0.600  
GSTA3  7  1423  1163  532  628  0.566  0.821  0.115  0.287  0.600  
GSTA4  16  1398  1127  524  610  0.212  0.522  0.076  0.863  0.902  
SOD2  5  1421  1143  533  621  0.002  0.175  0.011  0.141  0.600  
MDR1  33  1389  1138  522  621  0.213  0.490  0.031  0.277  0.600  
NAT1  11  1424  1156  533  627  0.385  0.814  0.115  0.197  0.600  
NAT2  15  1420  1158  531  629  0.366  0.709  0.268  0.509  0.761  
CAT  24  1321  1078  495  587  0.375  0.153  0.681  0.845  0.998  
GSTP1  7  1405  1145  530  620  0.566  0.195  0.444  0.297  0.902  
ALDH2  7  1426  1157  531  624  0.243  0.341  0.126  0.778  0.902  
GSTZ1  11  1404  1151  523  625  0.347  0.278  0.558  0.925  0.925  
NQO1  8  1402  1139  529  620  0.806  0.932  0.666  0.560  0.761  
MPO  7  1399  1142  527  621  0.852  0.946  0.889  0.596  0.761  
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Table 9. (Continued) 
COMT  29  1207  1040  470  575  0.982  0.887  0.970  0.217  0.600  
GSTT2  2  1420  1141  530  618  0.208  0.427  0.330  0.593  0.761  
Abbreviations: Ca, cases; CI, confidence interval; Co, controls; EAGLE, Environment And Genetics in Lung cancer Etiology; OR, odds ratio; NevAsb, never 
exposed to asbestos. 
Pinteraction values were calculated from 2-df log-likelihood ratio tests between the logistic model adjusted for the matching variables (age, sex, and residential area) and 
for tobacco smoking: cumulative exposure (pack-years), intensity (cigarettes per day), and years since quitting, categorized according to the quartiles of distribution of 
exposure among controls with and without interaction term for joint exposure to the genetic variant (grouped SNP “score” effect) and asbestos (never/any exposure). 
Both row and FDR corrected p-values are reported. 
Reference category: never exposed to both the genetic variant and asbestos. 
 
 
Not significant association were found in the subgroup analyses by gender and histology (data not shown). 
 
Pathway analysis 
Among the six pathways evaluated, the GSTM (p= 0.036) and antioxidant (p= 0.018) pathways, driven by GSTM4 and SOD2 
genes, respectively, resulted associated with asbestos exposure for lung cancer risk. The p values reported were adjusted for the number 
of SNPs within each gene, but not corrected for multiple comparisons since each pathway evaluated can be considered as an independent 
test (Table 10). 
  
Table 10. Association between the six pathways evaluated and ever/never asbestos exposure for lung cancer risk. All subjects. 
Pathway by Asbestos exposure N. gene  N. SNP  P value  Most significant genes  
Antioxidant Asbestos Never  2  29  0.173  CAT,SOD2  
Antioxidant Asbestos Ever  2  29  0.036  SOD2  
GST Asbestos Never  12  89  0.747  GSTA4,GSTM2,GSTM5,GSTCD,GSTA2,GSTA1,GSTA3  
GST Asbestos Ever  12  89  0.099  GSTM4,GSTM3  
GSTA Asbestos Never  4  29  0.454  GSTA4  
GSTA Asbestos Ever  4  29  0.317  GSTA3,GSTA2,GSTA1  
GSTM Asbestos Never  4  24  0.877  GSTM5,GSTM2  
GSTM Asbestos Ever  4  24  0.018  GSTM4,GSTM5,GSTM3  
NAT Asbestos Never  2  26  0.789  NAT2  
NAT Asbestos Ever  2  26  0.479  NAT1,NAT2  
ALL GENES Asbestos Never  23  293  0.906  GSTA4,UGT1A7,GSTCD,SOD2,MDR1,CAT,GSTP1  
ALL GENES Asbestos Ever  23  293  0.080  GSTM4,GSTM3,SOD2,MDR1  
Gene-level P-values across the candidate genes included in the selected biological pathway through an adaptive rank-truncated product (ARTP) method that uses a 
permutation algorithm for the evaluation of its significant level. 
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Haplotype analysis  
Interestingly, the haplotype analysis for the 4 SNPs in GSTM4 (which were in low LD for most SNPs pairs) revealed two 
haplotypes with a borderline association with lung cancer in the overall population. Using the most frequent haplotype as reference 
(TGAA, freq= 47%), the carriers of the haplotype CGAG (freq=4%), and CTAA (freq=6%) showed a positive (OR= 1.48; p-
value=0.062) and a negative (OR= 0.60; p-value=0.069) interaction with asbestos exposure, respectively (Table 11).  
 
Table 11. Frequency of haplotypes estimated for GSTM4 gene and interaction effect with never/ever asbestos exposure for lung cancer 
risk. All subjects. 
GSTM4  Locus1 Locus2 Locus3 Locus4 Haplotype 
frequency 
OR for 
interaction with 
asbestos 
P-value 
interaction 
Haplotype 1  C G A A 0.09 0.80 0.224 
Haplotype 2  C G A G 0.04 0.60 0.062 
Haplotype 3  C T A A 0.06 1.48 0.069 
Haplotype 4  C T G A 0.33 1.23 0.072 
Haplotypes rare (grouped) - - - - 0.01 3.48 0.173 
Haplotype most frequent  T G A A 0.47 Ref - 
ORs
 
calculated with unconditional logistic regression models, adjusted for the matching variables (age, sex, and residential area) and for tobacco smoking: 
cumulative exposure (pack-years), intensity (cigarettes per day), and years since quitting, categorized according to the quartiles of distribution of exposure among 
controls.  
Pinteraction values were calculated from 2-df log-likelihood ratio tests between the model with and without interaction term for joint exposure to the haplotype variant 
under evaluation and asbestos exposure (never/ever). 
 
Gene expression analysis 
To follow up the previous results, I focused this analysis on GSTM4 gene. Available Affymetrix probes 210912_x_at and 
204149_s_at for GSTM4 were used in the analysis. Gene expression levels from blood of controls and cases (data not shown), non-
involved lung tissue cells, and tumor cells of lung cases were consistently strongly down-regulated in subjects carrying the rs12745189 
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variant compared to subjects with normal variant of GSTM4. On the contrary, an upper-regulation was found for subjects carrying the 
rs668413 variant. No difference by asbestos exposure was found. Of note, the few subjects with gene expression data and exposure to 
asbestos rendered the estimates unstable. This effect was particularly clear in the non-involved (Table 12) compared to the tumour (Table 
13) tissue samples of the cases, likely because of the confounding effect of the high rate of chromosomal abnormalities present at the 
tumor level.  
  
Table 12. Fold-Change (FC) of expression between individuals with different genetic variants among never and ever exposed to asbestos 
in non-involved lung tissues samples of cases, in the EAGLE study, Lombardy, Italy, 2002-2005. All subjects. 
Gene Name  
Affymetrix 
Probe Name  
SNP Name  Comparison  
N 
Subjects  
FC  P-value  
N 
 Never  
FC  
Never  
P-value 
 Never  
N  
 Ever  
FC  
Ever  
P-value  
Ever  
GSTM4  204149_s_at  rs12745189  1) Trend  13  0.90 0.002  12  0.92 0.028  1  0.85 0.087  
GSTM4  204149_s_at  rs12745189  2) AA=0, AB=1  18  0.94 0.246  11  0.94 0.327  7  1.04 0.827  
GSTM4  204149_s_at  rs12745189_  3) AA=0, BB=1  8  0.79 0.001  5  0.84 0.027  3  0.81 0.246  
GSTM4  204149_s_at  rs12745189  4) AA=0, AB+BB=1  26  0.89 0.039  16  0.91 0.096  10  0.96 0.844  
GSTM4  210912_x_at  rs12745189  1) Trend  13  0.99 0.768  12  0.99 0.781  1  0.99 0.914  
GSTM4  210912_x_at  rs12745189  2) AA=0, AB=1  18  0.97 0.474  11  0.99 0.883  7  0.83 0.094  
GSTM4  210912_x_at  rs12745189  3) AA=0, BB=1  8  0.99 0.860  5  0.98 0.788  3  0.90 0.346  
GSTM4  210912_x_at  rs12745189  4) AA=0, AB+BB=1  26  0.97 0.542  16  0.99 0.816  10  0.85 0.137  
GSTM4  204149_s_at  rs668413  1) Trend  16  1.11 0.003  11  1.07 0.054  5  NA NA  
GSTM4  204149_s_at  rs668413  2) AA=0, AB=1  17  1.16 0.006  11  1.11 0.102  6  1.29 0.009  
GSTM4  204149_s_at  rs668413  3) AA=0, BB=1  6  1.21 0.010  6  1.14 0.078  0  NA NA  
GSTM4  204149_s_at  rs668413  4) AA=0, AB+BB=1  23  1.17 0.002  17  1.12 0.046  6  1.29 0.009  
GSTM4  210912_x_at  rs668413  1) Trend  16  0.99 0.774  11  1.01 0.847  5  NA NA  
GSTM4  210912_x_at  rs668413  2) AA=0, AB=1  17  0.94 0.175  11  0.96 0.479  6  0.91 0.117  
GSTM4  210912_x_at  rs668413  3) AA=0, BB=1  6  1.01 0.825  6  1.03 0.703  0  NA NA  
GSTM4  210912_x_at  rs668413  4) AA=0, AB+BB=1  23  0.96 0.323  17  0.98 0.741  6  0.91 0.117  
GSTM4  204149_s_at  rs560018  1) Trend  17  1.08 0.037  12  1.04 0.328  5  NA NA  
GSTM4  204149_s_at  rs560018  2) AA=0, AB=1  17  1.15 0.014  11  1.10 0.159  6  1.29 0.009  
             
47 
 
Table 12. (Continued) 
GSTM4  204149_s_at  rs560018  3) AA=0, BB=1  5  1.12 0.159  5  1.05 0.507  0  NA NA  
GSTM4  204149_s_at  rs560018  4) AA=0, AB+BB=1  22  1.14 0.012  16  1.08 0.172  6  1.29 0.009  
Abbreviations: Ca, cases; CI, confidence interval; Co, controls; EAGLE, Environment And Genetics in Lung cancer Etiology; FC, Fold-Change (FC = 2
ß
) of 
expression between individuals with different genetic variants among never and ever exposed to asbestos; N, number. 
Comparison: 1) Test for trend; 2) - 3) Additive model; 4) Dominant model. 
Reference category: never exposed to the genetic variant. Significant and nominally significant FCs are represented in bold and italics, respectively.  
 
  
Table 13. Fold-Change (FC) of expression between individuals with different genetic variants among never and ever exposed to asbestos 
in tumour lung tissues samples of cases, in the EAGLE study, Lombardy, Italy, 2002-2005. 
Gene 
Name  
Affymetrix 
 Probe Name  
SNP 
Name  
Comparison 
  
N Subjects  FC  P-value  N Never  FC Never  P-value Never  N Ever  FC Ever  P-value Ever  
GSTM4  204149_s_at  rs12745189  1) Trend  15  0.91 0.174  12  0.93 0.408  3  0.86 0.151  
GSTM4  204149_s_at  rs12745189  2) AA=0, AB=1  19  1.06 0.621  12  1.11 0.480  7  1.01 0.955  
GSTM4  204149_s_at  rs12745189  3) AA=0, BB=1  12  0.82 0.138  9  0.86 0.341  3  0.74 0.146  
GSTM4  204149_s_at  rs12745189  4) AA=0, AB+BB=1  31  0.96 0.712  21  0.99 0.966  10  0.92 0.635  
GSTM4  210912_x_at  rs12745189  1) Trend  15  0.95 0.081  12  0.94 0.075  3  0.98 0.776  
GSTM4  210912_x_at  rs12745189  2) AA=0, AB=1  19  0.96 0.483  12  0.97 0.661  7  1.00 0.981  
GSTM4  210912_x_at  rs12745189  3) AA=0, BB=1  12  0.90 0.081  9  0.89 0.070  3  0.96 0.787  
GSTM4  210912_x_at  rs12745189  4) AA=0, AB+BB=1  31  0.94 0.193  21  0.94 0.223  10  0.99 0.902  
GSTM4  204149_s_at  rs668413  1) Trend  18  1.07 0.296  15  1.07 0.445  3  1.16 0.151  
GSTM4  204149_s_at  rs668413  2) AA=0, AB=1  18  1.26 0.044  11  1.33 0.058  7  1.36 0.083  
GSTM4  204149_s_at  rs668413  3) AA=0, BB=1  10  1.10 0.464  7  1.06 0.707  3  1.35 0.146  
GSTM4  204149_s_at  rs668413  4) AA=0, AB+BB=1  28  1.20 0.076  18  1.22 0.132  10  1.36 0.060  
GSTM4  210912_x_at  rs668413  1) Trend  18  1.03 0.386  15  1.04 0.252  3  1.02 0.776  
GSTM4  210912_x_at  rs668413  2) AA=0, AB=1  18  1.08 0.124  11  1.13 0.028  7  1.04 0.767  
GSTM4  210912_x_at  rs668413  3) AA=0, BB=1  10  1.04 0.532  7  1.05 0.455  3  1.04 0.787  
GSTM4  210912_x_at  rs668413  4) AA=0, AB+BB=1  28  1.07 0.164  18  1.10 0.057  10  1.04 0.738  
GSTM4  204149_s_at  rs560018  1) Trend  21  1.07 0.317  17  1.09 0.341  4  1.09 0.463  
GSTM4  204149_s_at  rs560018  2) AA=0, AB=1  18  1.30 0.017  11  1.38 0.026  7  1.31 0.100  
GSTM4  204149_s_at  rs560018  3) AA=0, BB=1  7  1.03 0.842  5  1.04 0.848  2  1.08 0.718  
GSTM4  204149_s_at  rs560018  4) AA=0, AB+BB=1  25  1.22 0.052  16  1.26 0.075  9  1.25 0.141  
GSTM4  210912_x_at  rs560018  1) Trend  21  1.02 0.603  17  1.03 0.484  4  1.02 0.772  
GSTM4  210912_x_at  rs560018  2) AA=0, AB=1  18  1.08 0.116  11  1.16 0.007  7  0.99 0.903  
GSTM4  210912_x_at  rs560018  3) AA=0, BB=1  7  1.00 0.956  5  0.98 0.743  2  1.06 0.709  
GSTM4  210912_x_at  rs560018  4) AA=0, AB+BB=1  25  1.06 0.228  16  1.10 0.063  9  1.00 0.982  
GSTM4  204149_s_at  rs650985  1) Trend  42  NA  NA  29  NA  NA  13  NA  NA  
GSTM4  204149_s_at  rs650985  2) AA=0, AB=1  4  0.90 0.563  4  0.86 0.441  0  NA  NA  
GSTM4  204149_s_at  rs650985  3) AA=0, BB=1  0  NA  NA  0  NA  NA  0  NA  NA  
GSTM4  204149_s_at  rs650985  4) AA=0, AB+BB=1  4  0.90 0.563  4  0.86 0.441  0  NA  NA  
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Table 13. (Continued) 
GSTM4  210912_x_at  rs650985  1) Trend  42  NA  NA  29  NA  NA  13  NA  NA  
GSTM4  210912_x_at  rs650985  2) AA=0, AB=1  4  1.01 0.907  4  0.98 0.832  0  NA  NA  
GSTM4  210912_x_at  rs650985  3) AA=0, BB=1  0  NA  NA  0  NA  NA  0  NA  NA  
GSTM4  210912_x_at  rs650985  4) AA=0, AB+BB=1  4  1.01 0.907  4  -0.024  0.832  0  0.86 NA  
Abbreviations: Ca, cases; CI, confidence interval; Co, controls; EAGLE, Environment And Genetics in Lung cancer Etiology; FC, Fold-Change (FC = 2
ß
) of 
expression between individuals with different genetic variants among never and ever exposed to asbestos. 
Comparison: 1) Test for trend; 2) - 3) Additive model; 4) Dominant model. 
Reference category: never exposed to the genetic variant. . Significant and nominally significant FCs are represented in bold and italics, respectively. 
  
DISCUSSION 
In a large population-based case-control study, I found with a candidate gene approach that 
polymorphisms of the phase II metabolic GSTM4 gene may play a role in lung cancer susceptibility in 
association with asbestos exposure. In particular, on the additive model, the SNP rs668413 showed 
consistently across different levels of analysis, the strongest interaction with asbestos exposure. A 
possible role of the polymorphisms of SOD2 and GSTM3 genes has been found among women only, 
but the small number of subjects exposed to asbestos rendered the estimates unreliable. 
To the best of my knowledge, the GSTM4 gene has never been reported before in association 
with asbestos exposure and lung cancer risk. Another polymorphism of GSTM4 (rs506008) has been 
reported previously, but in association with lung cancer only (22). 
Among the GST family genes, the null variants of GSTM1 and GSTT1 have been more 
frequently evaluated in association with asbestos exposure for lung cancer risk and other chronic 
asbestos-related lung diseases, but with inconsistent results (37, 39, 57-59). 
Interestingly, the SNP rs668413 of the GSTM4 gene that showed the strongest interaction with 
asbestos exposure for lung cancer risk is in LD (r
2
 =0.74) with the SNP rs560018 of the GSTM4 gene, 
which showed a slightly weaker interaction in my dataset. The SNP rs560018 was recently found in 
association with lung cancer survival as a predictor of cisplatin chemotherapy response (71), so this 
result seems to suggest an important functional role of both these GSTM4 polymorphisms in the 
progression of lung cancer. This opens up an interesting hypothesis about the underlying biological 
mechanism between GSTM4 polymorphisms and asbestos in the pathogenesis of lung cancer, and may 
even suggest a possible target for future molecular diagnostic tests and genetic therapy.  
The interaction of the GSTM4 gene with asbestos exposure is biologically plausible since this 
gene encodes a soluble cytoplasmic glutathione S-transferases of the µ class involved in the 
detoxification of electrophilic compounds, including carcinogens, therapeutic drugs, environmental 
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toxins and products of oxidative stress, by conjugation with glutathione. The genes encoding the µ 
class of enzymes are organized in a gene cluster on chromosome 1p13.3 and are known to be highly 
polymorphic. These genetic variations can change an individual's susceptibility to carcinogens and 
toxins as well as affecting the toxicity and efficacy of certain drugs.  
This study has several strengths. Incident lung cancer cases and randomly sampled population 
controls allowed the impact of occupational exposures as PAF to be estimated at the community level. 
The large sample size with elevated participation rates gave adequate power to detect the main genetic 
effects and gene-asbestos interaction effects and to perform stratified analyses by gender and histology. 
Detailed information on occupational history and smoking exposure was collected face-to-face by 
trained interviewers. The occupational exposure assessment was highly robust, as detailed lifetime job 
histories were codified into ISCO codes and translated into levels of carcinogen exposure by blindly 
applying to case status a highly reliable JEM, thereby eliminating from this study the potential for 
differential misclassification of exposure to occupational carcinogens. This contrasts with a recent 
GWAS study (42) in which Wei et al. failed to find a significant gene-asbestos interaction for lung 
cancer, most likely because their asbestos exposure assessment relied entirely on self-reporting, leading 
to a significant issue of recall bias. My study had excellent genotyping, confirmed by the small number 
of subjects with <90% call rate, and a good gene coverage by the selected tagging SNPs. Another 
weakness of the study of Wei et al. was its low GWAS chip coverage, but by using a candidate gene 
approach, I was able to integrate the sensitivity of common GWAS chips with the specificity of 
customized TaqMan probes to achieve the best coverage of the 23 selected genes. In fact, commercial 
SNP chips capture most, though not all, common variations in the genome, and it could partly explain 
why of >900 GWASs published to date, very few reported significant gene-environment interactions 
(72). I employed a systematic, multi-level analysis (at SNP, gene, haplotype, and pathway levels) that 
takes into account the biological complexity of genetic networks. I also employed an integrative 
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analysis to evaluate the correlation between the genetic variants found associated with asbestos 
exposure for lung cancer risk and genetic functional variants at lung tissue level using gene expression 
data, although the small number of subjects with both gene expression data and asbestos exposure 
prevented me from finding any significant “signal” by asbestos exposure. A further strength of my 
study was the low exposure levels for occupational carcinogens in our study base, which is to be 
expected in a population-based study and which represents an ideal setting for testing gene-
occupational carcinogens interaction. In fact, higher exposure levels could have masked the expected 
small effect (1.1–1.5-fold) of common genetic variants. Finally, as stated previously, the homogeneous 
nature of the study base’s genetic background means there is minimal possibility of confounding by 
population stratification. 
This study also has some limitations. The low prevalence of exposure to occupational 
carcinogens among women prevented me from obtaining reliable risk estimates for them. No 
quantitative data for the occupational carcinogens selected were available, an inherent limitation of a 
large retrospective study such as this one, which means a semi-quantitative JEM is the best tool that 
can be applied. Residual confounding for smoking is always possible in a lung cancer study, although 
this was largely mitigated by carefully adjusting for smoking exposure in all of this study’s analyses. 
Perhaps the most important weakness of this study, and one that is shared by almost all previous 
candidate gene studies (56), is the lack of replication of my findings due to the unavailability of 
databases of comparable sample size and quality of asbestos exposure assessment. 
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CONCLUSIONS 
In a large population-based study, I have found an interaction between occupational exposure to 
asbestos and GSTM4 polymorphisms, in particular the SNP rs668413, in relation to lung cancer 
susceptibility. This finding has never previously been reported and should be validated in further 
studies.  
Considering my estimation that 18% of incident lung cancers (corresponding to ~800 cases) 
among men in Lombardy in 2005 were attributable to occupational exposure to asbestos, it is clear that 
we could have achieved an important goal for public health prevention had we been able to identify 
more susceptible subgroups and prevent them from being exposed.  
Furthermore, these results provide greater understanding of the role of the GST family enzymes, 
in particular in relation to asbestos exposure, and call for further research into the mechanisms 
underlying the observed differences. GSTM4 polymorphisms should be further evaluated as potential 
targets of molecular diagnostic tests and therapeutic strategies for asbestos-related lung cancer. In 
particular, an important impact of these findings for occupational health could be screening 
interventions focused on susceptible workers, and recognition of and compensation for occupational 
lung cancers that have so far proved impossible to differentiate from those that are tobacco-related. 
54 
 
REFERENCES 
 
1. American Cancer Society. Cancer Prevention & Early Detection Facts & Figures. Atlanta, GA:  
American Cancer Society; 2007.  
(http://www.cancer.org/downloads/STT/Global_Cancer_Facts_and_Figures_2007_rev.pdf). 
2. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 
2006. Ann Oncol 2007 Mar; 18(3):581-92. 
3. AIRT Working Group. Italian cancer figures. Report 2006: 1. Incidence, mortality and 
estimates. Epidemiol Prev 2006; 30(1 Suppl 2):8-147. 
4. Sun S, Shiller JH, Gazdar AF. Lung cancer in never smokers: a different disease. Nature 
Publishing Group 2007; 7:778-90. 
5. IARC Monographs on the Evaluation of Carcinogenic Risksto Humans. Lyon, France: 
International Agency for Research on Cancer;  
(http://monographs.iarc.fr/ENG/Classification/index.php). [Accessed January 03, 2010]. 
 6. Siemiatycki J, Richardson L, Straif K, et al. Listing occupational carcinogens. Environ Health 
Perspect 2004; 112:1447-59. 
7. Nelson DI, Concha-Barrientos M, Driscoll T, et al. The global burden of selected occupational 
diseases and injury risks: Methodology and summary. Am J Ind Med 2005; 48(6):400-418. 
8. Driscoll T, Nelson DI, Steenland K, et al. The global burden of disease due to occupational 
carcinogens. Am J Ind Med 2005; 48(6):419-431. 
9. De Matteis S, Consonni D, Bertazzi PA. Exposure to occupational carcinogens and lung cancer 
risk. Evolution of epidemiological estimates of attributable fraction. Acta Biomed 2008; 
79(Suppl 1):34-42. 
55 
 
10. Kauppinen T, Toikkanen J, Pedersen D, et al. Occupational exposure to carcinogens in the 
European Union. Occup Environ Med 2000;57(1):10-18.  
11. Mirabelli D. Estimated number of workers exposed to carcinogens in Italy, within the context of 
the European study CAREX (Italian). Epidemiol Prev 1999;23(4):346-359. 
12. Mirabelli D, Kauppinen T. Occupational exposures to carcinogens in Italy: an update of 
CAREX database. Int J Occup Environ Health 2005;11(1):53-63. 
13. Simonato L, Agudo A, Ahrens W, et al. Lung cancer and cigarette smoking in Europe: an 
update of risk estimates and an assessment of inter-country heterogeneity. Int J Cancer 2001; 
91: 876-87. 
14. Wright GS, Gruidl ME. Early detection and prevention of lung cancer. Curr Opin Oncol 
2000;12:143-8. 
15. Wood ME, Kelly K, Mullineaux LG, Bunn PA, Jr. The inherited nature of lung cancer: a pilot 
study. Lung Cancer 2000;30: 135-44. 
16. Matakidou A, Eisen T, Houlston RS. Systematic review of the relationship between family 
history and lung cancer risk. Br J Cancer 2005; 93: 825-33. 
17. Whittemore AS, Nelson LM. Study design in genetic epidemiology: theoretical and practical 
considerations. J Natl Cancer Inst Monogr 1999;(26):61-9.  
18. Khoury MJ, Cohen BH, Beaty TB. Fundamentals of Genetic Epidemiology. Ed. Oxford 
University Press, New York; 1993; pp. 151-163. 
19. Ottman R. An epidemiologic approach to gene-environment interaction. Genet Epidemiol 
1990;7:177-85. 
20. Bartsch H, Hietanen E. The role of individual susceptibility in cancer burden related to 
environmental exposure. Environ Health Perspect 1996 May;104 Suppl3:569-77. 
56 
 
21. Caporaso N, Goldstein A. Cancer genes: single and susceptibility: exposing the difference. 
Pharmacogenetics 1995; 5: 59-63. 
22. Liloglou T, Walters M, Maloney P, et al. A T2517C polymorphism in the GSTM4 gene is 
associated with risk of developing lung cancer. Lung Cancer 2002 Aug;37:143-6. 
23. Kiyohara C, Yoshimasu K, Shirakawa T, Hopkin JM. Genetic polymorphisms and 
environmental risk of lung cancer: a review. Rev Environ Health 2004 Jan-Mar;19(1):15-38. 
24. Liu G, Zhou W, Wang LI, et al. MPO and SOD2 polymorphisms, gender, and the risk of non-
small cell lung carcinoma. Cancer Lett 2004 Oct 8;214(1):69-79. 
25. Schneider J, Bernges U, Philipp M, Woitowitz HJ. GSTM1, GSTT1, and GSTP1 polymorphism 
and lung cancer risk in relation to tobacco smoking. Cancer Lett. 2004 May 10;208(1):65-74. 
26. Wenzlaff AS, Cote ML, Bock CH, et al. GSTM1, GSTT1 and GSTP1 polymorphisms, 
environmental tobacco smoke exposure and risk of lung cancer among never smokers: a 
population-based study. Carcinogenesis. 2005 Feb;26(2):395-401. Epub 2004 Nov 4. Erratum 
in: Carcinogenesis. 2005 Apr;26(4):865. 
27. Ye Z, Song H, Higgins JP, et al. Five glutathione s-transferase gene variants in 23,452 cases of 
lung cancer and 30,397 controls: meta-analysis of 130 studies. PLoS Med. 2006 Apr;3(4):e91. 
28. Zhang JY, Wang Y, Prakash C. Xenobiotic-metabolizing enzymes in human lung. Curr Drug 
Metab. 2006 Dec;7(8):939-48. 
29. Schwartz AG, Prysak GM, Bock CH, Cote ML. The molecular epidemiology of lung cancer. 
Carcinogenesis 2007 Mar;28(3):507-18. 
30. Zienolddiny S, Campa D, Lind H, et al. A comprehensive analysis of phase I and phase II 
metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. 
Carcinogenesis 2008 Jun;29(6):1164-9. 
57 
 
31. Rotunno, M., Yu, K., Lubin, J.H., et al. Phase I metabolic genes and risk of lung 
cancer:multiple polymorphisms and mRNA expression. PLoS One 2009; 4, e5652. 
32. Wang S, Wang F, Shi X, et al. Association between manganese superoxide dismutase 
(MnSOD) Val-9Ala polymorphism and cancer risk - A meta-analysis. Eur J Cancer 
2009;45:2874-81. 
33. Gallagher CJ, Ahn K, Knipe AL, et al. Association between haplotypes of manganese 
superoxide dismutase (SOD2), smoking, and lung cancer risk. Free Radic Biol Med 
2009;46(1):20-4. 
34. Anttila S, Raunio H, Hakkola J. Cytochrome P450-mediated pulmonary metabolism of 
carcinogens: regulation and cross-talk in lung carcinogenesis. Am J Respir Cell Mol Biol. 2011 
May;44(5):583-90. 
35. Rotunno M, Lam TK, Vogt A, et al. GSTM1 and GSTT1 copy numbers and mRNA expression 
in lung cancer. Mol Carcinog 2012;51 Suppl 1:E142-50. 
36. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. Lung cancer susceptibility: are we on 
our way to identifying a high-risk group? Future Oncol 2007;3:617-27. 
37. Anttila S, Luostarinen L, Hirvonen A, et al. Pulmonary expression of glutathione S-transferase 
M3 in lung cancer patients: association with GSTM1 polymorphism, smoking, and asbestos 
exposure. Cancer Res. 1995;55:3305-9. 
38. Saarikoski S.T., M. Reinikainen S., Anttila A., et al. Role of NAT2 deficiency in susceptibility 
to lung cancer among asbestos-exposed individuals, Pharmacogenetics 2000; 10:183–185. 
39. Stucker I., Boffetta P., Antilla S., et al. Lack of interaction between asbestos exposure and 
glutathione S-transferase M1 and T1 genotypes in lung carcinogenesis, Cancer Epidemiol. 
Biomarkers Prev 2001; 10: 1253–1258. 
58 
 
40. Schabath M.B., Spitz M.R., Delclos G.L., et al. Association between asbestos exposure, 
cigarette smoking, myeloperoxidase (MPO) genotypes, and lung cancer risk, Am J Ind Med 
2002; 42:29–37. 
41. Wang L.I., Neuberg D., Christiani D.C. Asbestos exposure, manganese superoxide dismutase 
(MnSOD) genotype, and lung cancer risk. J Occup Environ Med 2004; 46:556–564. 
42. Wei S, Wang LE, McHugh MK, et al. Genome-wide gene-environment interaction analysis for 
asbestos exposure in lung cancer susceptibility. Carcinogenesis. 2012;33:1531-7. 
43. Van Damme K, Casteleyn L, Heseltine E, et al. Individual susceptibility and prevention of 
occupational diseases: scientific and ethical issues. J Occup Environ Med 1995;37:91-9. 
44. Vineis P, Schulte P, McMichael AJ. Misconceptions about the use of genetic tests in 
populations. Lancet 2001; 357: 709-12. 
45. Bertazzi PA and Mutti A. Biomarkers, disease mechanisms and role in regulatory decisions. In: 
Wild C, Vineis P, Garte S. Molecular Epidemiology of Chronic Diseases.  Ed. Wiley-
Blackwell, Chicester, 2008; pp.243-254. 
46. Landi MT, Consonni D, Rotunno M, et al. Environment And Genetics in Lung cancer Etiology 
(EAGLE) study: an integrative population-based case-control study of lung cancer. BMC Public 
Health 2008;8:203. 
47. International Standard Industrial Classification of all economic activities (ISIC). United Nations 
Publications ST/STAT/M.4/Rev.2/Add.1, Sales No.: E.71.XVII.8. New York: Publishing 
Service United Nations, 1971. 
48. International Standard Classification of Occupations (ISCO, Revised 1968). Geneva, 
Switzerland: International Labor Office (ILO), ILO Publications, 1968, 2nd ed. 
49.  Goldberg M, Hémon D. Occupational epidemiology and assessment of exposure. Int J 
Epidemiol. 1993;22 Suppl 2:S5-9. 
59 
 
50. Bouyer J, Hémon D. Retrospective evaluation of occupational exposures in population-based 
case-control studies: general overview with special attention to job exposure matrices. Int J 
Epidemiol 1993;22 Suppl 2:S57-64 
51. McGuire V, Nelson LM, Koepsell TD, et al. Assessment of Occupational Exposures in 
community-based case-control studies. Ann Rev Public Health 1998; 19:35-53. 
52. Bouyer J, Hémon D. Studying the performance of a job exposure matrix. Int J Epidemiol. 
1993;22 Suppl 2:S65-71. 
53. Goldberg M, Kromhout H, Guenel P, et al. Job exposure matrices in industry. Int J Epidemiol 
1993;22 Suppl 2: S10-5. 
54. Kromhout H, Vermeulen R. Application of job-exposure matrices in studies of the general 
population: some clues to their performance. Eur Respir Rev 2001; 11: 80-90. 
55. Peters S, Vermeulen R, Cassidy A et al. Comparison of exposure assessment methods for 
occupational carcinogens in a multi-centre lung cancer case–control study. Occup Environ Med 
2010; 68:148–53. 
56. Tabor HK, Risch NJ, Myers RM. Candidate-gene approaches for studying complex genetic 
traits: practical considerations. Nat Rev Genet 2002; 5:391-7. 
57. Nelson HH, Kelsey KT. The molecular epidemiology of asbestos and tobacco in lung cancer. 
Oncogene. 2002;21:7284-8. 
58. Nymark P, Wikman H, Hienonen-Kempas T, Anttila S. Molecular and genetic changes in 
asbestos-related lung cancer. Cancer Lett. 2008;265:1-15. 
59. Neri M, Ugolini D, Dianzani I, et al. Genetic susceptibility to malignant pleural mesothelioma 
and other asbestos-associated diseases. Mutat Res. 2008;659:126-36. 
60 Bruzzi P, Green SB, Byar DP, et al. Estimating the population attributable risk for multiple risk 
factors using case-control data. Am J Epidemiol 1985;122:904-14. 
60 
 
61. Wacholder S, Benichou J, Heineman EF, Hartge P, Hoover RN. Attributable risk: advantages of 
a broad definition of exposure. Am J Epidemiol 1994;140:303-9. 
62. StataCorp. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP, 2009. 
63. Greenland S, Drescher K. Maximum likelihood estimation of the attributable fraction from 
logistic models. Biometrics 1993;49:865-72. 
64. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: a practical and powerful 
approach to multiple testing. J Royal Stat Soc Ser B; 1995; 57:289–300. 
65. Vallyathan V, Shi X. The role of oxygen free radicals in occupational and environmental lung 
diseases. Environ Health Perspect. 1997;105 Suppl 1:165-77. 
66. Ruosaari S, Hienonen-Kempas T, Puustinen A, et al. Pathways affected by asbestos exposure in 
normal and tumour tissue of lung cancer patients. BMC Med Genomics. 2008;1:55-64. 
67. Heintz NH, Janssen-Heininger YM, Mossman BT. Asbestos, lung cancers, and mesotheliomas: 
from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol. 
2010;42:133-9. 
68. Liu G, Beri R, Mueller A, Kamp DW. Molecular mechanisms of asbestos-induced lung 
epithelial cell apoptosis. Chem Biol Interact. 2010;188:309-18. 
69. Yu K, Li Q, Bergen AW, Pfeiffer RM, et al. Pathway analysis by adaptive combination of P-
values. Genet Epidemiol 2009;33:700-9. 
70. De Matteis S, Consonni D, Lubin JH, et al. Impact of occupational carcinogens on lung cancer 
risk in a general population. Int J Epidemiol 2012; 41: 711-21. 
71. Moyer AM, Sun Z, Batzler AJ, et al. Glutathione pathway genetic polymorphisms and lung 
cancer survival after platinum-based chemotherapy. Cancer Epidemiol Biomarkers Prev. 
2010;19:811-21. 
61 
 
72. Hindorff LA, Sethupathy P, Junkins H, et al. Potential etiologic and functional implications of 
genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A. 
2009;106:9362-7. 
